{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":749,"total_is_capped":false,"direct_labels_cover":2,"predictions_cover":749,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"640f9589c59b","filters":{"topic":"Melanoma and MAPK Pathways"}},"results":[{"id":"W2128542677","doi":"10.1056/nejmoa1103782","title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7688,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Vemurafenib; Medicine; Dacarbazine; Interim analysis; Internal medicine; Adverse effect; Melanoma; Oncology; Rash; Dabrafenib; Progression-free survival; Nausea; Clinical trial; Cancer research; Metastatic melanoma; Chemotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.0159994996001733,"gpt":0.22066546399615,"spread":0.2046659643959767,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003928004,0.0001248027,0.0002336213,0.0000854891,0.00001877638,0.000003868903,0.0001179444,0.00006452744,0.00004816574],"category_scores_gemma":[0.00005677231,0.00007046247,0.00002316869,0.00008589045,0.000064758,0.000007591206,0.00001177616,0.0001458482,7.827972e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000009118105,"about_ca_system_score_gemma":0.0001512673,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001793062,"about_ca_topic_score_gemma":0.0007822742,"domain_scores_codex":[0.9992082,0.00006205835,0.0002691626,0.0001274367,0.0001788419,0.0001542667],"domain_scores_gemma":[0.9993707,0.00001888711,0.0002131266,0.0001332506,0.0001172269,0.000146794],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01845354,0.0003154675,0.1182243,0.00008120484,0.0004332068,0.002334859,0.005860635,0.00005098737,0.7096181,0.0004183417,0.001395247,0.1428142],"study_design_scores_gemma":[0.2656659,0.08820555,0.2284072,0.0009640936,0.0004694975,0.01354204,0.00273776,0.0001264636,0.3452905,0.0007269816,0.05277717,0.001086796],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930816,0.0003796256,0.002767026,0.0002959798,0.0002129697,0.00008507541,0.000001178631,0.000002975023,0.003173555],"genre_scores_gemma":[0.9969872,0.00006286081,0.001361816,0.0001094582,0.001195598,0.000001278251,0.00001310823,0.00001478134,0.0002538865],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3643276,"threshold_uncertainty_score":0.2873376,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2128035403","doi":"10.1056/nejmoa1412082","title":"Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5352,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Royal Victoria Hospital; BC Cancer Agency","funders":"","keywords":"Nivolumab; Melanoma; Mutation; Medicine; Cancer research; Biology; Genetics; Internal medicine; Cancer; Immunotherapy; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.007510965650476341,"gpt":0.2337536327064622,"spread":0.2262426670559859,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000690329,0.0001163396,0.0002651505,0.00009567281,0.00002078341,0.00000601595,0.000127858,0.00008492848,0.00003687906],"category_scores_gemma":[0.0003523449,0.00008141409,0.00004070977,0.00008025477,0.00004194567,0.000005419823,0.00001602342,0.0001321502,0.000003573893],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001301641,"about_ca_system_score_gemma":0.00009131656,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007931194,"about_ca_topic_score_gemma":0.0002255187,"domain_scores_codex":[0.9990199,0.0001343741,0.0003776746,0.0001260449,0.0001804025,0.0001616178],"domain_scores_gemma":[0.9993515,0.00003053774,0.0002248204,0.0001448877,0.00009346887,0.0001548038],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001881538,0.0001269173,0.09006483,0.0000633016,0.0001243753,0.0002426277,0.001319857,0.0002210656,0.4466833,0.0002523715,0.01600127,0.4430185],"study_design_scores_gemma":[0.2167009,0.03622241,0.05128434,0.00101824,0.000324874,0.0072732,0.0003703437,0.0005501881,0.1266525,0.002560381,0.5562831,0.0007594659],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921202,0.0009757536,0.002882851,0.0007961017,0.0003298967,0.00008358491,7.371794e-7,0.000004047619,0.002806837],"genre_scores_gemma":[0.9960175,0.0001661948,0.0003792318,0.0003310781,0.002530392,9.744093e-7,0.00002383771,0.00001298728,0.0005377925],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5402818,"threshold_uncertainty_score":0.331997,"prediction_status":"machine_predicted_unvalidated"},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W2107495112","doi":"10.1128/mmbr.00031-10","title":"Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases","year":2011,"lang":"en","type":"review","venue":"Microbiology and Molecular Biology Reviews","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3257,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Kinase; Biology; Cell biology; MAPK/ERK pathway; p38 mitogen-activated protein kinases; Ribosomal s6 kinase; Mitogen-activated protein kinase; Protein kinase A; Mitogen-activated protein kinase kinase; MAP2K7; MAP kinase kinase kinase; ASK1; Signal transduction; Cyclin-dependent kinase 2; P70-S6 Kinase 1; Protein kinase B","retraction":null,"screen_n_in":null,"score":{"opus":0.02984821007226111,"gpt":0.2585359077245694,"spread":0.2286876976523083,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004889088,0.000487778,0.001022762,0.00004442847,0.000166385,0.00001109193,0.0002671656,0.0008221394,0.000008943827],"category_scores_gemma":[0.0001003435,0.0002319614,0.0002456684,0.0001106592,0.0007417451,0.000003903871,0.0003314817,0.0003218426,0.000001848737],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000006225433,"about_ca_system_score_gemma":0.00008341836,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001647149,"about_ca_topic_score_gemma":0.00001421034,"domain_scores_codex":[0.9973797,0.001189359,0.0005397662,0.0006164965,0.00001386117,0.000260768],"domain_scores_gemma":[0.9987201,0.00003780467,0.0005924171,0.0005555106,0.00004674799,0.00004742535],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002492343,0.00001853493,0.00001915143,0.001265451,0.0001590921,3.24009e-7,0.00001619497,4.265234e-9,0.76629,0.0008747806,0.0001279814,0.2312036],"study_design_scores_gemma":[0.0001468745,0.0002740206,0.00002795713,0.0009008679,0.0002057911,0.0001289671,0.000007465124,4.021704e-8,0.1483332,0.0001661898,0.849584,0.0002246706],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.02620418,0.9715248,0.0001899429,0.00003654891,0.0001206205,0.00170921,0.0001195445,0.000006631122,0.00008851785],"genre_scores_gemma":[0.009080611,0.989669,0.00005790283,0.0001951954,0.0000591491,0.0002279507,0.0005837946,0.00002929635,0.00009706588],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.849456,"threshold_uncertainty_score":0.945911,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2166262263","doi":"10.1016/s0140-6736(12)60868-x","title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","year":2012,"lang":"en","type":"article","venue":"The Lancet","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2960,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital","funders":"GlaxoSmithKline","keywords":"Dabrafenib; Dacarbazine; Medicine; Internal medicine; Melanoma; Hazard ratio; Clinical endpoint; Adverse effect; Oncology; Phases of clinical research; Progression-free survival; Clinical trial; Randomized controlled trial; Gastroenterology; Surgery; Metastatic melanoma; Chemotherapy; Cancer; Vemurafenib; Confidence interval; Cancer research","retraction":null,"screen_n_in":null,"score":{"opus":0.05743917274431475,"gpt":0.3392784182895699,"spread":0.2818392455452552,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001234021,0.0002062793,0.0007175959,0.00003404228,0.00008094819,0.00005928758,0.0005963035,0.00008007403,0.00009657974],"category_scores_gemma":[0.0004614054,0.0001298184,0.00007746924,0.0001067947,0.0000565674,0.00001365738,0.0001752056,0.000136237,0.00005135158],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001671501,"about_ca_system_score_gemma":0.0001000747,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004019395,"about_ca_topic_score_gemma":0.00005429997,"domain_scores_codex":[0.9981779,0.0005254332,0.0003939501,0.0002437205,0.000127222,0.0005317463],"domain_scores_gemma":[0.9989784,0.0001369854,0.0001709823,0.0005646097,0.00003468851,0.0001142889],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.761595,0.001889063,0.0001764193,0.00001926949,0.000289919,0.00001738283,0.0004449646,0.000006265577,0.2254488,0.000198787,0.008666135,0.001247956],"study_design_scores_gemma":[0.9557571,0.0005414794,0.00005798559,0.000010149,0.0001093677,0.00001388895,0.00006662909,0.0002727981,0.02926674,0.00005695965,0.01365161,0.0001952784],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9887992,0.001163702,0.0001977401,0.000401394,0.0004911134,0.003805909,0.00004677706,0.00001726225,0.005076862],"genre_scores_gemma":[0.9961952,0.00007801665,0.0004386537,0.0007019794,0.0009406756,0.0005565254,0.0001734339,0.00002452211,0.0008909822],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1961821,"threshold_uncertainty_score":0.529384,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3036759197","doi":"10.1038/s41580-020-0255-7","title":"ERK signalling: a master regulator of cell behaviour, life and fate","year":2020,"lang":"en","type":"review","venue":"Nature Reviews Molecular Cell Biology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1202,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Canadian Institutes of Health Research","keywords":"Cell biology; MAPK/ERK pathway; Kinase; Biology; Cell growth; Cell fate determination; Extracellular; Cell; Signal transduction; Intracellular; Protein kinase A; Cell signaling; Regulator; Cell metabolism; Biochemistry; Transcription factor","retraction":null,"screen_n_in":null,"score":{"opus":0.02423147105711939,"gpt":0.280338448925497,"spread":0.2561069778683777,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0004151052,0.0008906986,0.002954596,0.000135216,0.00004848852,0.00001997868,0.0006430559,0.002651531,0.0000393802],"category_scores_gemma":[0.000166305,0.000685719,0.001127388,0.0002410203,0.0001656481,0.000002856562,0.0004643806,0.001031134,0.00004726786],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001723541,"about_ca_system_score_gemma":0.0003285641,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00000208982,"about_ca_topic_score_gemma":0.000001119882,"domain_scores_codex":[0.9960365,0.0008258116,0.001238013,0.001271387,0.0001426388,0.0004856866],"domain_scores_gemma":[0.9975317,0.00003593718,0.001111099,0.0008643043,0.00009764224,0.0003593235],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005316558,0.0001867667,0.0000363835,0.04064915,0.0003573079,0.0001214218,0.00002547558,3.168288e-7,0.3102205,0.0002915961,0.003508069,0.6445498],"study_design_scores_gemma":[0.0003037116,0.000490658,5.262186e-7,0.001139284,0.0008313317,0.00003219335,0.000002465999,9.176763e-7,0.0163828,0.00001642982,0.9801877,0.0006120501],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002217076,0.9954433,0.0004956075,0.00002259957,0.0003000662,0.001535016,0.0001707343,0.00001501998,0.001795892],"genre_scores_gemma":[0.0009035242,0.9944055,0.002098944,0.0004859003,0.000306619,0.000126653,0.001275356,0.0001178796,0.0002796374],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9766796,"threshold_uncertainty_score":0.9995594,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1983833034","doi":"10.1038/sj.onc.1210414","title":"The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition","year":2007,"lang":"en","type":"review","venue":"Oncogene","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1104,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute for Research in Immunology and Cancer","funders":"","keywords":"Biology; Cell biology; Cell cycle; MAPK/ERK pathway; Kinase; Protein kinase A; Cyclin-dependent kinase 2; Mitogen-activated protein kinase; Signal transduction; Cyclin; Cyclin-dependent kinase 4; Anti-apoptotic Ras signalling cascade; ASK1; Cell growth; Mitogen-Activated Protein Kinase 3; Mitogen-activated protein kinase kinase; Cell; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.04216164765805923,"gpt":0.3239142138717571,"spread":0.2817525662136978,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003960138,0.0004059791,0.0006052844,0.00005676885,0.0001623479,0.00002666883,0.0005325988,0.0004807631,0.00003265891],"category_scores_gemma":[0.00008506144,0.0002297521,0.0005852017,0.000276172,0.00009403426,0.000002449739,0.0001400926,0.0001928538,0.00003846404],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004058423,"about_ca_system_score_gemma":0.0004816537,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001644151,"about_ca_topic_score_gemma":0.00002903021,"domain_scores_codex":[0.9980183,0.000258636,0.0005812211,0.0004993135,0.0002767077,0.0003658244],"domain_scores_gemma":[0.9982915,0.00002279769,0.0003377956,0.001077211,0.0001208643,0.0001498569],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001004519,0.00007308775,5.896993e-8,0.0006123864,0.0001027596,0.000008523986,0.00002776273,2.895246e-7,0.464059,0.00003984173,0.0004192705,0.5345566],"study_design_scores_gemma":[0.0002832531,0.0003190477,1.856339e-7,0.0007911184,0.00009058681,0.00003103933,0.000008449757,2.184606e-7,0.3913176,0.000007842008,0.6069753,0.0001753822],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.02156582,0.9737856,0.0002159369,0.0000838852,0.0005037543,0.002507774,0.0003312127,0.00001356191,0.0009924989],"genre_scores_gemma":[0.006668458,0.9770139,0.0003684035,0.0003733168,0.001411636,0.0007811887,0.0007749018,0.0002137692,0.01239447],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.606556,"threshold_uncertainty_score":0.9369019,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2155461614","doi":"10.1056/nejmoa1105358","title":"<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors","year":2012,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1028,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"University of California, San Francisco; Plexxikon; European Organisation for Research and Treatment of Cancer; Jonsson Cancer Center Foundation; National Cancer Institute; University of California, Los Angeles; Cancer Research UK; Wellcome Trust; California Institute of Technology","keywords":"HRAS; Vemurafenib; Neuroblastoma RAS viral oncogene homolog; KRAS; Cancer research; MAPK/ERK pathway; Carcinogenesis; V600E; Cell growth; Mutation; Biology; Medicine; Kinase; Melanoma; Cancer; Internal medicine; Gene; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.006657930907524172,"gpt":0.2093037642751884,"spread":0.2026458333676642,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002265243,0.0001233508,0.0002181907,0.0001439493,0.00001722492,0.000003291442,0.00008173066,0.0000773773,0.00001885762],"category_scores_gemma":[0.00009950801,0.00008182491,0.00002718378,0.0001306899,0.00004196037,0.000008650726,0.00001382652,0.0001642756,0.000001552962],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002447781,"about_ca_system_score_gemma":0.00008009286,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001563493,"about_ca_topic_score_gemma":0.0002129805,"domain_scores_codex":[0.9990736,0.00007285052,0.000350545,0.00009766142,0.0001876509,0.0002177211],"domain_scores_gemma":[0.9994264,0.00003387804,0.0001690614,0.0001051315,0.00007374243,0.0001917672],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0005912785,0.0002318995,0.9501253,0.00001393543,0.000009829279,0.0001100812,0.0006420643,0.00006279113,0.04191819,0.000004693761,0.001443286,0.004846607],"study_design_scores_gemma":[0.1631027,0.01801462,0.62368,0.000365689,0.0001961308,0.002012728,0.0007365068,0.00002093713,0.142799,0.00005173871,0.04838484,0.0006351144],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972275,0.0007750358,0.00003400996,0.0001640674,0.00020481,0.0001009421,0.000002672776,0.000002034511,0.001488966],"genre_scores_gemma":[0.99834,0.00003774539,0.00009300914,0.0001280658,0.001171028,0.000001217211,0.00004024537,0.00001392174,0.0001747986],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3264454,"threshold_uncertainty_score":0.3336723,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2111404068","doi":"10.1016/s1470-2045(14)70012-9","title":"Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":978,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Medical Research Council; National Health and Medical Research Council; National Cancer Institute; National Institutes of Health; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Genentech; F. Hoffmann-La Roche","keywords":"Vemurafenib; Dacarbazine; Medicine; Internal medicine; Melanoma; Population; Oncology; Progression-free survival; Metastatic melanoma; Chemotherapy; Cancer research; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.0286159142605539,"gpt":0.3339014764236995,"spread":0.3052855621631456,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001177818,0.0001563678,0.0006707869,0.00004802115,0.00006217627,0.00001137866,0.0003044803,0.0001244429,0.000008163393],"category_scores_gemma":[0.0002849355,0.0001159535,0.00003185165,0.00008858667,0.0002112981,0.000007345978,0.00027289,0.0001105545,9.119393e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001212918,"about_ca_system_score_gemma":0.00008710973,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001272675,"about_ca_topic_score_gemma":0.0004234443,"domain_scores_codex":[0.9982852,0.000672221,0.0004170081,0.0003223228,0.00008594214,0.0002173029],"domain_scores_gemma":[0.9989133,0.0003558692,0.0002529949,0.0003504614,0.00006953995,0.00005783344],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1172393,0.005918985,0.007428633,0.0001367205,0.0006628266,0.00005551344,0.006525965,0.00001631739,0.7131909,0.003644714,0.0005567797,0.1446234],"study_design_scores_gemma":[0.7619356,0.02393308,0.09174892,0.00008302523,0.0003469131,0.0001807637,0.001429412,0.0005928241,0.1112797,0.0009786859,0.006951217,0.0005398071],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950681,0.0003128666,0.0003243542,0.0002511799,0.0001079808,0.001132981,0.00004151374,0.000004699333,0.002756287],"genre_scores_gemma":[0.9989465,0.0001276906,0.0003713453,0.0001959751,0.0001076383,0.00004793514,0.00005143386,0.00001399194,0.0001375275],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6446963,"threshold_uncertainty_score":0.4728448,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1985928174","doi":"10.1038/nature13121","title":"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma","year":2014,"lang":"en","type":"article","venue":"Nature","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":910,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Melanoma; Cancer research; Vemurafenib; V600E; MEK inhibitor; Epidermal growth factor receptor; MAPK/ERK pathway; EGFR inhibitors; Selumetinib; Biology; Medicine; Oncogene; Kinase; Cancer; Mutation; Internal medicine; Cell cycle; Cell biology","retraction":null,"screen_n_in":null,"score":{"opus":0.004767629710370415,"gpt":0.2128412747391986,"spread":0.2080736450288282,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001218024,0.00007943068,0.00008062323,0.00004016306,0.00002968011,0.000008810853,0.00004329411,0.0005067392,0.000005683494],"category_scores_gemma":[0.00008042052,0.0000766923,0.00001893457,0.00007942917,0.00001585163,0.000002980912,0.00005119746,0.0002393863,0.000006454883],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00000920425,"about_ca_system_score_gemma":0.00001582646,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000005487367,"about_ca_topic_score_gemma":0.0004859781,"domain_scores_codex":[0.9994556,0.00003664582,0.00007335767,0.0002413281,0.00006627911,0.000126793],"domain_scores_gemma":[0.9997286,0.000007861106,0.00002280638,0.0001515935,0.00003215212,0.00005697077],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0003377441,0.0000352625,0.003461499,0.00003600648,0.00001154883,0.00001879191,0.0001567752,0.000008306651,0.932695,0.006442371,0.0547847,0.002011989],"study_design_scores_gemma":[0.0009865216,0.000476347,0.02001337,0.00008485762,0.000007327263,0.00001640008,0.00008017864,0.00001655278,0.5632014,0.00133663,0.4134837,0.0002967069],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9853071,0.0008099783,0.0003770652,0.0005689037,0.00009495654,0.0001216968,0.00001353638,0.000007206596,0.01269954],"genre_scores_gemma":[0.9954227,0.00002409477,0.001265063,0.001355821,0.0001434365,0.000007862604,0.00003556911,0.000008225506,0.001737177],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3694936,"threshold_uncertainty_score":0.3908437,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2620651944","doi":"10.1016/s1470-2045(17)30429-1","title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":775,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Dabrafenib; Trametinib; Medicine; Melanoma; Asymptomatic; Clinical endpoint; Oncology; MEK inhibitor; Internal medicine; Brain metastasis; Phases of clinical research; Clinical trial; Metastatic melanoma; Cancer; Metastasis; Vemurafenib; Cancer research; Biology; MAPK/ERK pathway","retraction":null,"screen_n_in":null,"score":{"opus":0.06803476530507808,"gpt":0.3693754023310494,"spread":0.3013406370259713,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001075781,0.0003349062,0.0008194628,0.00005171337,0.0003483401,0.0001561475,0.001681199,0.0002517022,0.00006511562],"category_scores_gemma":[0.0007101872,0.0002211395,0.00006520339,0.00006675661,0.0003341887,0.00002530478,0.0006534105,0.0002996603,0.00002496742],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007123301,"about_ca_system_score_gemma":0.0003307384,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002896097,"about_ca_topic_score_gemma":0.001660997,"domain_scores_codex":[0.9973586,0.0006460969,0.0004608295,0.0006459358,0.000207905,0.0006805973],"domain_scores_gemma":[0.9976071,0.0001708946,0.000490352,0.001492497,0.0000873243,0.0001518039],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.690795,0.02335631,0.03574027,0.000156332,0.001639196,0.0007052405,0.00181584,0.00008625597,0.1251538,0.002000413,0.03676676,0.08178461],"study_design_scores_gemma":[0.7498624,0.01787678,0.01772174,0.00005458676,0.0002205665,0.00003365165,0.0001591615,0.0003824114,0.01797722,0.0001619809,0.1947546,0.0007949995],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921213,0.0000980471,0.00009739659,0.00167236,0.0005507236,0.002255279,0.0002516194,0.00001913588,0.002934173],"genre_scores_gemma":[0.9956285,0.00004354232,0.001455953,0.001267872,0.000546632,0.0002453519,0.0003463201,0.00004430251,0.0004214908],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1579878,"threshold_uncertainty_score":0.9017808,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2165575701","doi":"10.1016/j.cell.2012.02.053","title":"Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer","year":2012,"lang":"en","type":"article","venue":"Cell","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":744,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Institute of General Medical Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Institute of Environmental Health Sciences; Canadian Institutes of Health Research","keywords":"Kinome; Triple-negative breast cancer; MEK inhibitor; Biology; Cancer research; MAPK/ERK pathway; Reprogramming; Receptor tyrosine kinase; Kinase; Trametinib; Gene knockdown; Cancer; Cell biology; Breast cancer; Apoptosis; Biochemistry; Cell; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.007236532849522338,"gpt":0.2387321196060584,"spread":0.2314955867565361,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000297684,0.00007144643,0.00008684576,0.0000497557,0.00001521869,0.000002973116,0.00005910307,0.00007258557,0.00001432867],"category_scores_gemma":[0.00005793825,0.00005733639,0.00003616082,0.0001734694,0.00002603098,0.000003348011,0.0000632396,0.000061292,0.000003245708],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000362841,"about_ca_system_score_gemma":0.00005353506,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002021805,"about_ca_topic_score_gemma":0.0004274807,"domain_scores_codex":[0.9993369,0.0001235547,0.0001500874,0.0001476764,0.000056753,0.0001850125],"domain_scores_gemma":[0.9996731,0.0000122253,0.00005676361,0.0001912467,0.00002450699,0.00004210007],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0004034046,0.0000688546,0.01163918,0.00001260025,0.000002401853,0.000001381222,0.0004913711,0.00003440939,0.9867434,0.000003943559,0.00005091489,0.0005481601],"study_design_scores_gemma":[0.0005455526,0.00005507107,0.2699282,0.00002637858,0.000003017184,0.000003852719,0.0001729299,0.00002137676,0.7283266,0.00001375215,0.0008255906,0.0000776088],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9988793,0.0002956725,0.00004083091,0.0001305164,0.0001372311,0.0002455275,0.00003785046,0.000002557165,0.0002304773],"genre_scores_gemma":[0.9992431,0.00001297372,0.0001938973,0.00008007341,0.00002864897,0.00004636607,0.0000135667,0.000008673926,0.0003726386],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2584168,"threshold_uncertainty_score":0.233811,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2054946171","doi":"10.1038/nrm3979","title":"Regulation of RAF protein kinases in ERK signalling","year":2015,"lang":"en","type":"review","venue":"Nature Reviews Molecular Cell Biology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":702,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université du Québec à Montréal; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Kinase; Allosteric regulation; MAPK/ERK pathway; Signalling; Cell biology; Function (biology); Suppressor; Phosphorylation; Chemistry; Biology; Biochemistry; Enzyme; Cancer; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.02828340218594011,"gpt":0.317174288496513,"spread":0.2888908863105729,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00109836,0.0006258423,0.00234116,0.0002493307,0.00002323381,0.00000914787,0.0005600764,0.002498543,0.00002233143],"category_scores_gemma":[0.0003332285,0.0004897008,0.0007593574,0.0003922363,0.00009632801,0.000003031423,0.0002078424,0.0007894658,0.00003364235],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000507836,"about_ca_system_score_gemma":0.0004192099,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000008360352,"about_ca_topic_score_gemma":0.000009614839,"domain_scores_codex":[0.9961216,0.001217004,0.001228489,0.0008756322,0.000149826,0.0004074149],"domain_scores_gemma":[0.9978906,0.00002519943,0.001005719,0.000815851,0.0001468934,0.0001157641],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002417453,0.000102682,0.000003128303,0.01461717,0.00006693138,0.00002095577,0.000006726089,0.000003219084,0.2511881,0.0004406501,0.0007114283,0.7328148],"study_design_scores_gemma":[0.0002625528,0.0002896339,3.909991e-7,0.003937528,0.0001914929,0.00001111371,0.00000148841,0.000001332055,0.01847644,0.0001416935,0.97624,0.0004462765],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002136944,0.9937434,0.000327297,0.000006064539,0.0002116143,0.002365679,0.00006223233,0.000009802789,0.003060278],"genre_scores_gemma":[0.0009561759,0.9942365,0.001407898,0.00005752017,0.0002185183,0.0002891647,0.002499426,0.00007125144,0.0002634893],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9755286,"threshold_uncertainty_score":0.9997554,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2137723371","doi":"10.1200/jco.2007.12.7837","title":"Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":700,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"National Center for Advancing Translational Sciences","keywords":"Medicine; Internal medicine; Clinical trial; Oncology; Multivariate analysis; Progression-free survival; Clinical endpoint; Cancer; Randomized controlled trial; Overall survival","retraction":null,"screen_n_in":null,"score":{"opus":0.3381739698257792,"gpt":0.5079362980495256,"spread":0.1697623282237464,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02543428,0.0002898672,0.007325118,0.0003156968,0.0001161405,0.00001025304,0.0003718096,0.0004401949,0.0002765723],"category_scores_gemma":[0.02305509,0.0001791484,0.002720757,0.0002423327,0.0001708039,0.00002013169,0.0002308289,0.0003328012,1.87011e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002126191,"about_ca_system_score_gemma":0.0006620433,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001126377,"about_ca_topic_score_gemma":0.000269496,"domain_scores_codex":[0.9888242,0.004380866,0.005735274,0.0004269781,0.0003399313,0.0002926752],"domain_scores_gemma":[0.9900641,0.004545237,0.004106763,0.0003907689,0.000501358,0.0003917573],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1431172,0.03772935,0.00220515,0.0001759882,0.3033172,0.001385028,0.001885455,0.0003603512,0.3683147,0.001048717,0.02033772,0.1201231],"study_design_scores_gemma":[0.1662403,0.4003233,0.002598356,0.00003825156,0.1869288,0.0001929746,0.0006067398,0.0007207312,0.03701869,0.0004723645,0.2038988,0.0009607392],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915048,0.00239901,0.002402961,0.001381879,0.0006263736,0.0009362538,0.0006548919,0.000001865973,0.00009194635],"genre_scores_gemma":[0.9800194,0.0008993881,0.01675012,0.0006793403,0.001080297,0.00007867885,0.0001896584,0.00001984771,0.0002832868],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.362594,"threshold_uncertainty_score":0.9851741,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2789665281","doi":"10.1038/s41388-018-0171-x","title":"Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations","year":2018,"lang":"en","type":"review","venue":"Oncogene","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":559,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; McGill University; McGill University Health Centre","funders":"","keywords":"Biology; Druggability; Melanoma; V600E; Cancer research; Mutation; Mutant; MAPK/ERK pathway; Cancer; Kinase; Colorectal cancer; Targeted therapy; Genetics; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.1142483572554173,"gpt":0.3914304546005842,"spread":0.277182097345167,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001017753,0.0002313216,0.0003780094,0.00009268635,0.0001395748,0.00007349857,0.0001585601,0.0002794656,0.0000914313],"category_scores_gemma":[0.00002125797,0.0002132303,0.0002138945,0.0001274854,0.00003664511,0.000009834243,0.00003025027,0.00009061343,0.00001872216],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000721765,"about_ca_system_score_gemma":0.002863835,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006637113,"about_ca_topic_score_gemma":0.0009506592,"domain_scores_codex":[0.9989061,0.00005805974,0.0003469962,0.0003819649,0.00008898215,0.0002178695],"domain_scores_gemma":[0.9994141,0.00003917731,0.0001690931,0.0002280768,0.00008353253,0.00006604896],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003639311,0.0001557177,0.000008371786,0.002642519,0.0004484906,0.000003135455,0.000103894,0.000197088,0.01270144,0.00507729,0.01927871,0.959347],"study_design_scores_gemma":[0.000269974,0.0001280053,0.000001853558,0.0004141477,0.0001443519,0.00001453724,0.00003157944,0.00003113346,0.0006425841,0.0006008098,0.9974906,0.0002304025],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00007583779,0.985908,0.01098115,0.00006019682,0.0004834259,0.0007312409,0.0002690786,0.00001211992,0.001478927],"genre_scores_gemma":[0.0001986886,0.9862614,0.001825138,0.0001003339,0.001978403,0.0008465594,0.003312061,0.00004821207,0.005429186],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9782119,"threshold_uncertainty_score":0.8695278,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4211123988","doi":"10.1016/s0140-6736(13)60802-8","title":"Cutaneous melanoma","year":2013,"lang":"en","type":"review","venue":"The Lancet","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":532,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"","keywords":"Melanoma; Medicine; Immunotherapy; Oncology; Targeted therapy; Lymph node; Sentinel lymph node; Immunology; Cancer research; Internal medicine; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.05328027353009913,"gpt":0.3025350624953358,"spread":0.2492547889652367,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001104482,0.0002664718,0.000868702,0.00001807938,0.0000631552,0.0000391221,0.0007363395,0.0002756132,0.0001161682],"category_scores_gemma":[0.00003966643,0.0001470963,0.0002533423,0.00005028141,0.00005282008,6.94393e-7,0.0001880713,0.0001953263,0.0008289501],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001223646,"about_ca_system_score_gemma":0.000140996,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000008301818,"about_ca_topic_score_gemma":0.00000468849,"domain_scores_codex":[0.9990307,0.0001268476,0.0002164859,0.0002391815,0.00008770804,0.0002990396],"domain_scores_gemma":[0.9987064,0.0000237805,0.0001421112,0.001053664,0.00002140173,0.00005262374],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000005401413,0.00001091849,0.000002569641,0.001674095,0.0001428981,0.00001339716,0.0000149258,1.247785e-7,0.0001294524,0.0002790211,0.1249485,0.8727787],"study_design_scores_gemma":[0.00008087237,0.00007735732,5.360565e-7,0.0003663726,0.0001294923,0.0004693745,0.000003389038,3.517955e-7,0.00006462286,0.00005145637,0.9985573,0.000198869],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00007283627,0.9829134,0.00001871221,0.00005717116,0.000319566,0.0004153162,0.00008258899,0.00002055007,0.01609989],"genre_scores_gemma":[0.00003038306,0.9878349,0.0001035068,0.0001949039,0.003537425,0.0001195085,0.000342411,0.00004441476,0.007792516],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8736088,"threshold_uncertainty_score":0.999949,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1985309852","doi":"10.1038/nature08314","title":"A dimerization-dependent mechanism drives RAF catalytic activation","year":2009,"lang":"en","type":"article","venue":"Nature","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":498,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Institute for Research in Immunology and Cancer; Université de Montréal; Lunenfeld-Tanenbaum Research Institute","funders":"Canadian Institutes of Health Research","keywords":"MAPK/ERK pathway; Cell biology; Kinase; Receptor tyrosine kinase; Signal transduction; Tyrosine kinase; Chemistry; Phosphorylation; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.0041429794295503,"gpt":0.2257316560204767,"spread":0.2215886765909263,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004233814,0.00009224045,0.00006644335,0.00002772981,0.00005377418,0.00001527449,0.0001060373,0.0006389422,0.00001353541],"category_scores_gemma":[0.00005421894,0.00008327388,0.00003871127,0.00005588747,0.000008153744,0.000004052123,0.0000213358,0.0002474226,0.00000911203],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000008113127,"about_ca_system_score_gemma":0.00003462938,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000001560033,"about_ca_topic_score_gemma":0.000003146687,"domain_scores_codex":[0.9994698,0.00001562924,0.00007738436,0.0002072739,0.0001107295,0.0001192404],"domain_scores_gemma":[0.9996678,0.000003247837,0.00004217059,0.0001994211,0.00004466654,0.00004269037],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00001988063,0.00002830093,0.00004535622,0.000003216343,0.00001051846,0.000001806001,0.00002908767,0.000006450645,0.9916519,0.004525813,0.001748986,0.001928669],"study_design_scores_gemma":[0.0002788393,0.0001504582,0.002458544,0.000007128881,0.000008605952,0.000008138293,0.00002126341,0.00002886323,0.9843262,0.001707478,0.01088067,0.0001237708],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9826142,0.0004302528,0.008133221,0.001011571,0.00036805,0.0002372907,0.00001632832,0.000039878,0.007149192],"genre_scores_gemma":[0.9962217,0.00003050626,0.0003482845,0.001414799,0.0002525854,0.000004757073,0.0003314098,0.000008363446,0.001387596],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01360748,"threshold_uncertainty_score":0.4928107,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2594529508","doi":"10.1016/s1470-2045(17)30180-8","title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":491,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Dacarbazine; Medicine; Neuroblastoma RAS viral oncogene homolog; Hazard ratio; Melanoma; Internal medicine; Clinical endpoint; Population; Adverse effect; Oncology; Progression-free survival; Randomized controlled trial; Vemurafenib; Cancer; Confidence interval; Chemotherapy; Metastatic melanoma; Cancer research; Colorectal cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.05756250214883237,"gpt":0.3665577832550817,"spread":0.3089952811062494,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006973488,0.0002467896,0.0006357944,0.00003361656,0.0002603738,0.0000720822,0.001251689,0.0002007466,0.00004622863],"category_scores_gemma":[0.0005765868,0.0001608461,0.00004649681,0.00005256501,0.0002060015,0.00001620898,0.0004937221,0.0002162379,0.00002596397],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004662613,"about_ca_system_score_gemma":0.0002077226,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004543337,"about_ca_topic_score_gemma":0.0004320239,"domain_scores_codex":[0.9981857,0.0003340799,0.0003460566,0.000476838,0.0001503516,0.0005069915],"domain_scores_gemma":[0.9981112,0.0001248706,0.0004152753,0.0011606,0.00008506836,0.0001030144],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9413875,0.001788273,0.002504655,0.00001270507,0.000165384,0.00003757251,0.0001018991,0.000006033888,0.03283108,0.0001461193,0.001164539,0.01985425],"study_design_scores_gemma":[0.8913029,0.01335624,0.002974534,0.00001950546,0.00007182873,0.000003948862,0.00003868295,0.00003722726,0.007827321,0.00002135625,0.08407936,0.0002670525],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9826784,0.0001287684,0.00002180999,0.0005276924,0.0009830422,0.00214652,0.00007460718,0.00001237254,0.01342677],"genre_scores_gemma":[0.9974016,0.0001467308,0.000793519,0.0003195207,0.0006383751,0.0002641666,0.0001961016,0.00003031827,0.0002096896],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08291481,"threshold_uncertainty_score":0.6559113,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2029575024","doi":"10.1038/nm.2166","title":"Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma","year":2010,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":472,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"National Cancer Institute; National Institute on Drug Abuse; Canadian Institutes of Health Research; Weill Cornell Medical College; Howard Hughes Medical Institute","keywords":"Cancer research; Fusion gene; Prostate cancer; Chromoplexy; Cancer; Biology; Anaplastic lymphoma kinase; Oncogene; Oncogene Proteins; Melanoma; Viral Oncogene; Gene; Medicine; Lung cancer; Regulation of gene expression; Genetics; PCA3; Cell cycle; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.005012724505159081,"gpt":0.2506074112941852,"spread":0.2455946867890262,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001775448,0.000108871,0.0001447918,0.00004324556,0.00002921526,0.000002222746,0.0001407011,0.0001739666,0.00004205384],"category_scores_gemma":[0.0001171866,0.00006455775,0.0000228337,0.0001431407,0.0001227962,0.000001918622,0.00006941281,0.0003565573,2.631381e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000006768522,"about_ca_system_score_gemma":0.0000800239,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003498758,"about_ca_topic_score_gemma":0.002016419,"domain_scores_codex":[0.9993139,0.00002625924,0.0001503179,0.0002087427,0.0001455139,0.0001552565],"domain_scores_gemma":[0.999543,0.000008486601,0.00008523508,0.0002493217,0.00006010644,0.00005392302],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00006629722,0.00001953903,0.08329366,0.00003954306,0.0000138077,0.0000052807,0.0001068257,7.399539e-7,0.9028267,0.00006957695,0.001731841,0.01182621],"study_design_scores_gemma":[0.002656343,0.0003015559,0.1796234,0.0001665917,0.00002674816,0.00001979064,0.00007560123,0.00001161373,0.7031873,0.0001151561,0.1136662,0.0001496186],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9883709,0.008426319,0.000001515033,0.001251062,0.0008168074,0.0002398106,0.00004198496,0.000003146949,0.0008484553],"genre_scores_gemma":[0.9976619,0.0007219921,0.00004363047,0.0004397213,0.0003529479,0.0000396533,0.00002128667,0.00001054244,0.0007083616],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1996393,"threshold_uncertainty_score":0.2632589,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2102646127","doi":"10.1016/j.molcel.2005.10.022","title":"Wild-Type and Mutant B-RAF Activate C-RAF through Distinct Mechanisms Involving Heterodimerization","year":2005,"lang":"en","type":"article","venue":"Molecular Cell","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":421,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Institute of Cancer Research; Cancer Research UK; Cancer Research Institute","keywords":"Biology; Mutant; Genetics; Wild type; Cell biology; Mutation; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.007918534931107038,"gpt":0.2099768426774062,"spread":0.2020583077462992,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008976748,0.0002144374,0.0001534101,0.00002763243,0.0001045436,0.00004147685,0.0001349159,0.0001622705,0.00002675023],"category_scores_gemma":[0.00004131327,0.0002095202,0.00005732423,0.0001033065,0.00004315456,0.00001064084,0.0001427146,0.00009299471,0.00002416731],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001369613,"about_ca_system_score_gemma":0.00004124302,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001691593,"about_ca_topic_score_gemma":0.0000137218,"domain_scores_codex":[0.9988774,0.00006823238,0.0001867771,0.0004465343,0.0001397262,0.0002813513],"domain_scores_gemma":[0.999403,0.000005769679,0.00008725241,0.0003509329,0.00006297413,0.00009010057],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00003681409,0.0000481194,0.0001313135,0.00002269743,0.00002205102,0.00001757989,0.00008239333,0.00006122611,0.9978448,0.0004152485,0.0001241672,0.001193573],"study_design_scores_gemma":[0.0004615802,0.0002369077,0.0001492318,0.000011182,0.00002697062,0.00001596524,0.00002817102,0.0002670034,0.9677972,0.0003103862,0.03043327,0.0002621781],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9443386,0.001050157,0.05114244,0.0001080896,0.0001584011,0.0001903213,0.00000968872,0.00002944734,0.002972826],"genre_scores_gemma":[0.9931319,0.0001467771,0.005347722,0.0006314732,0.0001217582,0.00001044602,0.0002010939,0.00004299009,0.0003657991],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0487933,"threshold_uncertainty_score":0.8543985,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2151507583","doi":"10.1634/theoncologist.12-4-426","title":"Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors","year":2007,"lang":"en","type":"review","venue":"The Oncologist","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":418,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Sorafenib; Medicine; Clinical trial; Pharmacokinetics; Refractory (planetary science); Pharmacology; Oncology; Drug; Toxicity; Safety profile; Phases of clinical research; Internal medicine; Medical physics; Adverse effect; Hepatocellular carcinoma","retraction":null,"screen_n_in":null,"score":{"opus":0.07306418962376841,"gpt":0.4061245175451803,"spread":0.3330603279214119,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002528225,0.0003788288,0.002687295,0.00008980659,0.00003630333,0.000004059964,0.0003572225,0.0002220103,0.00001672947],"category_scores_gemma":[0.0008430054,0.0002237392,0.0002925249,0.0001736305,0.0003485554,0.000005403218,0.0002122409,0.0002769179,0.000001033106],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004359872,"about_ca_system_score_gemma":0.0003932847,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001022978,"about_ca_topic_score_gemma":0.000007816653,"domain_scores_codex":[0.9969282,0.0009414047,0.00125477,0.0004084771,0.0002099864,0.0002571342],"domain_scores_gemma":[0.9968787,0.0003263841,0.002046304,0.0005431658,0.0001365758,0.00006879766],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002108481,0.0008143817,0.00003217136,0.03626572,0.0001599065,0.000019974,0.000009222145,6.872654e-7,0.001041626,0.000005128835,0.0003713441,0.9591714],"study_design_scores_gemma":[0.006354828,0.01096288,0.0004801076,0.04862639,0.001515669,0.00003559519,0.00001116645,0.000001256548,0.004239493,0.000004528715,0.9271909,0.0005771985],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01443642,0.982094,0.0000513755,0.00001695019,0.0001241218,0.002377074,0.0003499078,0.000005730272,0.0005444643],"genre_scores_gemma":[0.0152949,0.983953,0.0001913688,0.00005513,0.0000918709,0.00006934455,0.0002504617,0.00003608641,0.00005783149],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9585941,"threshold_uncertainty_score":0.912382,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2774483419","doi":"10.1158/2159-8290.cd-17-1119","title":"First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study","year":2017,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":418,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Phenomenome Discoveries (Canada)","funders":"","keywords":"Medicine; Adverse effect; Nausea; Neuroblastoma RAS viral oncogene homolog; Cohort; Response Evaluation Criteria in Solid Tumors; Tolerability; Internal medicine; Cancer; Pharmacokinetics; MEK inhibitor; Oncology; Gastroenterology; MAPK/ERK pathway; Pharmacology; Clinical trial; Phases of clinical research; Kinase; Colorectal cancer; KRAS","retraction":null,"screen_n_in":null,"score":{"opus":0.01034731323142016,"gpt":0.2735128579624377,"spread":0.2631655447310176,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001155503,0.0001680101,0.0002547683,0.00005304682,0.00007669353,0.00003957673,0.0001380122,0.00007598925,0.000002243331],"category_scores_gemma":[0.00008071801,0.0001374561,0.00002887987,0.00004927182,0.00007591431,0.00004792871,0.0001128104,0.00007771653,4.521464e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000336349,"about_ca_system_score_gemma":0.00009725372,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002037705,"about_ca_topic_score_gemma":0.001968547,"domain_scores_codex":[0.9988205,0.00003368854,0.0003483804,0.0004353083,0.0001553776,0.0002067477],"domain_scores_gemma":[0.9991203,0.000009965534,0.0002842321,0.0004768349,0.00005369795,0.00005497839],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01245333,0.002048809,0.6263078,0.0001345477,0.00005113744,0.00003422829,0.001013987,0.0003631028,0.3484898,0.00000810243,0.0001100311,0.008985083],"study_design_scores_gemma":[0.02126631,0.002807692,0.8086477,0.0003999554,0.00001998333,7.107826e-7,0.000317183,0.0001303006,0.1658493,0.00001527935,0.0002779361,0.0002676592],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9986793,0.0001352964,0.0000242673,0.00004088403,0.0001575628,0.0006388788,0.0001783482,0.000003671636,0.0001417546],"genre_scores_gemma":[0.99954,0.00006314118,0.00002863531,0.0000210609,0.00008221703,0.00008258001,0.00009075343,0.00001804945,0.00007360236],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1826405,"threshold_uncertainty_score":0.5605297,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1977852460","doi":"10.1073/pnas.0905139106","title":"Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival","year":2009,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":381,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; York University; Emerald Foundation; National Cancer Institute; National Science Foundation; National Institutes of Health; Cancer Research Institute","keywords":"Melanoma; Immune system; Tumor-infiltrating lymphocytes; Gene expression profiling; Mitotic index; Oncology; Metastasis; Survival analysis; Medicine; Cancer research; Immunology; Internal medicine; Biology; Gene expression; Cancer; Immunotherapy; Gene; Mitosis","retraction":null,"screen_n_in":null,"score":{"opus":0.0371327176768018,"gpt":0.3280444458010932,"spread":0.2909117281242914,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001124766,0.00006532917,0.000155114,0.00006783702,0.00005719343,0.00000570628,0.0002541763,0.00005569249,0.000001822492],"category_scores_gemma":[0.000647512,0.00004633221,0.000047736,0.0002133696,0.0003152286,0.00001773616,0.00009985689,0.00009654307,7.475116e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000004806716,"about_ca_system_score_gemma":0.00003952827,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000006094186,"about_ca_topic_score_gemma":2.102107e-7,"domain_scores_codex":[0.9988639,0.00001633522,0.0004379612,0.0001953484,0.0003789106,0.0001075899],"domain_scores_gemma":[0.9994122,0.0000558324,0.0003804647,0.0000103331,0.0001170135,0.00002420477],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00003100531,0.00008554,0.1212571,0.00004354205,0.00001129025,1.199876e-8,0.0001120184,0.00002744155,0.8731186,0.002376884,0.00003102169,0.002905595],"study_design_scores_gemma":[0.0001633525,0.0002529134,0.403527,0.00007765242,0.000006235539,0.000002266066,0.0002259367,0.0005111152,0.5928643,0.002304139,0.00001795101,0.00004714666],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.998024,0.0003280338,0.000004685263,0.0003156517,0.00001985558,0.0001423391,0.00001243217,0.000001732304,0.001151252],"genre_scores_gemma":[0.9987254,0.00004998749,0.001119856,0.00004717627,0.00002817292,0.00000358924,4.476902e-7,0.000001957568,0.00002346874],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2822699,"threshold_uncertainty_score":0.1889373,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2064854415","doi":"10.1042/bj20110289","title":"Regulation and function of the RSK family of protein kinases","year":2011,"lang":"en","type":"review","venue":"Biochemical Journal","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":376,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Biology; Gene isoform; Kinase; Effector; Cell biology; Ribosomal s6 kinase; Caenorhabditis elegans; Function (biology); Signal transduction; MAPK/ERK pathway; SH3 domain; Genetics; Receptor tyrosine kinase; Gene; PI3K/AKT/mTOR pathway; P70-S6 Kinase 1","retraction":null,"screen_n_in":null,"score":{"opus":0.0339763056822595,"gpt":0.2545984915611993,"spread":0.2206221858789398,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001519905,0.0001545774,0.0003762385,0.00003550195,0.0000332092,0.000006264922,0.0001751135,0.0003103163,0.00001067478],"category_scores_gemma":[0.00007699337,0.00009410482,0.0002735461,0.00006319056,0.0001125336,0.000001793273,0.0001044293,0.0001604167,7.17106e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000074564,"about_ca_system_score_gemma":0.0001477634,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000002819635,"about_ca_topic_score_gemma":2.399428e-7,"domain_scores_codex":[0.999132,0.00009224188,0.0004073886,0.0001578422,0.0001090568,0.0001014085],"domain_scores_gemma":[0.9990866,0.000007000717,0.0005344052,0.0002299569,0.00008893035,0.00005307088],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000432551,0.0000443204,0.0000125185,0.002050029,0.0001022255,4.270996e-7,0.000005178823,2.529191e-8,0.6870347,0.0001419372,0.001448906,0.3091164],"study_design_scores_gemma":[0.000191296,0.0002649447,0.0001845325,0.002968905,0.0003045457,0.000118611,0.000006581813,2.035708e-7,0.1766224,0.0002024881,0.8189781,0.0001573666],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.02897961,0.9702268,0.0001029644,0.000003204693,0.0001404712,0.0002291566,0.00002517437,0.000001550601,0.0002910847],"genre_scores_gemma":[0.01547779,0.9837239,0.0001795945,0.000008366004,0.000337979,0.000009949388,0.00004194307,0.0000186878,0.0002018185],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8175293,"threshold_uncertainty_score":0.3837483,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2038264590","doi":"10.1158/2159-8290.cd-12-0386","title":"Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma","year":2012,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":373,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"Cancer Research UK; Wellcome Trust","keywords":"Vemurafenib; Dasatinib; Cancer research; Src family kinase; Melanoma; Tyrosine kinase; EGFR inhibitors; Metastasis; Epidermal growth factor receptor; Gefitinib; Medicine; Signal transduction; Kinase; Proto-oncogene tyrosine-protein kinase Src; Biology; Cancer; Oncogene; Internal medicine; Cell cycle; Cell biology","retraction":null,"screen_n_in":null,"score":{"opus":0.02031716774709106,"gpt":0.2606265288370754,"spread":0.2403093610899843,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002595705,0.0002573769,0.0002598318,0.00007003294,0.00008907971,0.00006155108,0.0001791152,0.0001873787,0.00006613028],"category_scores_gemma":[0.000103313,0.0002254572,0.0001068913,0.0001787958,0.00006801676,0.00005876386,0.0001408245,0.0001563969,0.00001896143],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001032969,"about_ca_system_score_gemma":0.0002321607,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000917827,"about_ca_topic_score_gemma":0.0004222788,"domain_scores_codex":[0.9983709,0.00008411908,0.0003471811,0.0004277549,0.0001860206,0.0005840473],"domain_scores_gemma":[0.9993317,0.00003689135,0.0001334766,0.0003128461,0.00004004668,0.0001450062],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0003980209,0.00008954854,0.03275634,0.0001039116,0.00002927694,0.00001275457,0.0002273161,0.00002028233,0.9587085,0.0002636302,0.006372783,0.001017661],"study_design_scores_gemma":[0.00114032,0.0001350782,0.008789263,0.0003406414,0.0000205195,0.000004339799,0.0005304193,0.000003086883,0.9029054,0.00004964646,0.08553758,0.0005437054],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9847311,0.01104988,0.0002406629,0.00009265142,0.0008911021,0.0002243018,0.0001373397,0.00002018794,0.002612828],"genre_scores_gemma":[0.9927188,0.0004758967,0.0004958298,0.0005826821,0.001759268,0.0001088822,0.0001104026,0.00004734872,0.003700891],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07916479,"threshold_uncertainty_score":0.9193876,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2171367970","doi":"10.1200/jco.2012.44.7888","title":"Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":363,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Jonsson Comprehensive Cancer Center; University of Texas MD Anderson Cancer Center; University of California, Los Angeles; Peter MacCallum Cancer Centre; Plexxikon; Vanderbilt University; Moffitt Cancer Center; Genentech; University of Pittsburgh; F. Hoffmann-La Roche; Vanderbilt-Ingram Cancer Center; York University; University of Pennsylvania; Massachusetts General Hospital; GlaxoSmithKline","keywords":"Vemurafenib; Medicine; Neuroblastoma RAS viral oncogene homolog; MAPK/ERK pathway; Cancer research; Melanoma; Kinase; Phosphorylation; Internal medicine; Cancer; Metastatic melanoma; KRAS; Biology; Colorectal cancer; Cell biology","retraction":null,"screen_n_in":null,"score":{"opus":0.01935879750345848,"gpt":0.3406378477840598,"spread":0.3212790502806013,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007347963,0.0001002196,0.0005939146,0.00006856093,0.00001179173,0.000004050723,0.0001404532,0.0001190092,0.00001327359],"category_scores_gemma":[0.0005284789,0.00006937583,0.00008124469,0.00006689969,0.00006388313,0.000008220682,0.00005412144,0.0001803969,0.0000034778],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001405697,"about_ca_system_score_gemma":0.0001815303,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007110828,"about_ca_topic_score_gemma":0.0000564256,"domain_scores_codex":[0.9983845,0.0002828089,0.0008817883,0.000154685,0.0001464136,0.0001498248],"domain_scores_gemma":[0.9985882,0.0002571171,0.000637396,0.0001187903,0.0002144146,0.0001840787],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.01711114,0.004916823,0.4016236,0.00050686,0.001245922,0.0003072163,0.0002490652,0.00009365167,0.4269823,0.001757,0.004678069,0.1405283],"study_design_scores_gemma":[0.01298603,0.02768454,0.9277217,0.0001148436,0.0001396783,0.00001949504,0.00004678668,0.00002400834,0.02454813,0.001635378,0.004867116,0.0002123448],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997168,0.0001201601,0.001579987,0.000261138,0.0002641339,0.000261152,0.000003545965,0.000001000234,0.0003408701],"genre_scores_gemma":[0.9912798,0.00003677414,0.007975697,0.0005242741,0.00006681668,0.000007728568,0.000003103973,0.000010087,0.00009565429],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5260981,"threshold_uncertainty_score":0.2829064,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2130044807","doi":"10.1038/sj.embor.embor939","title":"An essential function of the mitogen‐activated protein kinase Erk2 in mouse trophoblast development","year":2003,"lang":"en","type":"article","venue":"EMBO Reports","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":359,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"Canadian Institutes of Health Research; Centre National de la Recherche Scientifique; Cancer Research Society","keywords":"Trophoblast; Cell biology; Biology; MAPK/ERK pathway; Protein kinase A; Kinase; Embryonic stem cell; Embryogenesis; Embryo; Cell growth; Placenta; Fetus; Genetics; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.006149139100158751,"gpt":0.2061387202618671,"spread":0.1999895811617083,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001761861,0.0001054726,0.0001025098,0.0000295687,0.00004786138,0.000007817669,0.00006058173,0.0001010571,0.00002933277],"category_scores_gemma":[0.00006402569,0.00008186165,0.0000466635,0.00008565835,0.00002864784,0.00000377636,0.00002727399,0.00006098828,0.000001207024],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001527012,"about_ca_system_score_gemma":0.0001979337,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002480636,"about_ca_topic_score_gemma":0.00008206915,"domain_scores_codex":[0.999081,0.00008441637,0.0002949903,0.0002629146,0.0001282426,0.0001484475],"domain_scores_gemma":[0.9993346,0.000001344018,0.0001679676,0.0003981628,0.00005174669,0.00004616454],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00005027729,0.0001218647,0.003997123,0.00001286281,0.00001511222,0.00003064965,0.00005438907,0.00003006951,0.9951814,0.00002955336,0.00009550151,0.0003811798],"study_design_scores_gemma":[0.0002227934,0.0001003784,0.006578143,0.00001151413,0.000004588596,0.00003354808,0.0000365211,0.000001467295,0.9822171,0.00003170066,0.01066109,0.0001011024],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9982888,0.00005546327,0.0003119578,0.000005373116,0.0003073766,0.0002939798,0.000001644311,0.000006907866,0.0007284872],"genre_scores_gemma":[0.9984421,0.000001431885,0.0002581024,0.00001969916,0.00004364601,0.00004199776,0.0000361842,0.00001375253,0.001143148],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01296426,"threshold_uncertainty_score":0.3338221,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3034783173","doi":"10.1016/j.trecan.2020.05.009","title":"Clinical Development of BRAF plus MEK Inhibitor Combinations","year":2020,"lang":"en","type":"review","venue":"Trends in cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":352,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Daiichi Sankyo Company; Bristol-Myers Squibb Canada; Genentech; European Society for Medical Oncology; Exelixis; Prometheus; Roche; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; American Society of Clinical Oncology; AstraZeneca; Novartis; Spectrum Pharmaceuticals; Amgen; GlaxoSmithKline","keywords":"MEK inhibitor; Cancer research; Chemistry; Pharmacology; Medicine; MAPK/ERK pathway; Phosphorylation; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.1354341508561493,"gpt":0.4400165371099267,"spread":0.3045823862537773,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000164028,0.000219612,0.0008646386,0.00007391772,0.0000228941,0.000005333845,0.0002344593,0.0003420271,0.00009966312],"category_scores_gemma":[0.0000327265,0.0001916239,0.0002676852,0.0002240063,0.00005440331,0.000001203328,0.0001521826,0.0002042527,0.00001187777],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006791219,"about_ca_system_score_gemma":0.0008235517,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000108919,"about_ca_topic_score_gemma":0.0002431131,"domain_scores_codex":[0.9984587,0.00009593155,0.0007795777,0.0003878278,0.0001165444,0.0001613954],"domain_scores_gemma":[0.9993481,0.00002237963,0.0002717726,0.0002452823,0.00003419783,0.00007828287],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000006810905,0.00008359848,0.00002200482,0.0009697064,0.00009557474,0.00000448799,0.00004407761,4.386228e-7,0.00001608187,0.00003463255,0.003645694,0.9950769],"study_design_scores_gemma":[0.0004585377,0.00009965745,0.00004397725,0.0009974837,0.00008362276,0.000002375327,0.000004857221,0.000001474078,0.0001921909,0.000002868134,0.9979141,0.0001988976],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002174879,0.996649,0.00003739501,0.00002564289,0.0005874684,0.0001386632,0.0001106503,0.000006907127,0.002226816],"genre_scores_gemma":[0.000402512,0.9966151,0.0007502579,0.00003838304,0.0003662276,0.0001587158,0.0005951886,0.00003145873,0.001042201],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.994878,"threshold_uncertainty_score":0.7814198,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2948884915","doi":"10.1038/s41591-019-0476-5","title":"Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma","year":2019,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":326,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; National Institutes of Health; Nature","keywords":"Medicine; Dabrafenib; Melanoma; Trametinib; Pembrolizumab; MEK inhibitor; Immunotherapy; Discontinuation; Blockade; Internal medicine; Oncology; Adverse effect; Combination therapy; Targeted therapy; MAPK/ERK pathway; Vemurafenib; Immunology; Pharmacology; Cancer research; Cancer; Kinase; Metastatic melanoma; Biology; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.002431315230869503,"gpt":0.2083139023884205,"spread":0.205882587157551,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001855429,0.0001747786,0.0002400927,0.00008048589,0.00002743876,0.000006757976,0.00008104361,0.0003232635,0.00007144124],"category_scores_gemma":[0.00003015291,0.0001199872,0.00002208429,0.0001247407,0.0000832571,0.00000432307,0.00003228992,0.0003051044,0.000006008216],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001216733,"about_ca_system_score_gemma":0.00004090485,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003282883,"about_ca_topic_score_gemma":0.00007699897,"domain_scores_codex":[0.999082,0.00004224757,0.000176571,0.0003277577,0.0001698331,0.0002015405],"domain_scores_gemma":[0.9995309,0.00001538638,0.00006917084,0.0002718589,0.00004714176,0.00006551688],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0004770285,0.00004251824,0.01161036,0.00003238181,0.00003094706,0.00003802577,0.0001355893,0.000001299959,0.9855612,0.0003427294,0.0004655044,0.001262443],"study_design_scores_gemma":[0.01414676,0.005704735,0.07601328,0.0003089034,0.00002966909,0.0002544421,0.0002525736,0.00004681145,0.8693783,0.0003063181,0.03312759,0.0004305818],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922408,0.003322185,0.00004728528,0.001247916,0.0002009618,0.0003193176,0.000007167115,0.00001340058,0.002600932],"genre_scores_gemma":[0.9972904,0.0002791233,0.0001257514,0.001344347,0.0002173055,0.0000111544,0.0001692161,0.00002277393,0.0005398668],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1161828,"threshold_uncertainty_score":0.4892937,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2948740360","doi":"10.1038/s41591-019-0448-9","title":"Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma","year":2019,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":323,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"Merck Sharp and Dohme","keywords":"Dabrafenib; Trametinib; Pembrolizumab; Melanoma; Medicine; Mutant; Cancer research; Oncology; Internal medicine; Vemurafenib; Biology; Immunotherapy; Metastatic melanoma; Genetics; MAPK/ERK pathway; Cancer; Phosphorylation; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.005862682673053842,"gpt":0.2530370359029938,"spread":0.24717435322994,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002692339,0.0001915097,0.0002878423,0.0000899418,0.00002419442,0.000007087542,0.0001601653,0.0004585745,0.0002521366],"category_scores_gemma":[0.0002379393,0.0001268656,0.00003166889,0.0001303794,0.00007875059,0.000003542676,0.00006908543,0.0003807806,0.00001709737],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001208632,"about_ca_system_score_gemma":0.00007191191,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000220766,"about_ca_topic_score_gemma":0.0001307109,"domain_scores_codex":[0.9988576,0.00005820324,0.0002224838,0.000420418,0.0001777629,0.0002635841],"domain_scores_gemma":[0.9994159,0.00003893359,0.00006286393,0.0003360267,0.00003568506,0.0001105285],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001489889,0.00006627198,0.009792275,0.0001044483,0.00003766956,0.0001053412,0.0002337041,0.000002259604,0.9778183,0.0005505081,0.004946956,0.004852421],"study_design_scores_gemma":[0.03385881,0.006605373,0.06111197,0.0004405701,0.00008961878,0.001218236,0.000819965,0.0002196475,0.4112166,0.0003472147,0.4830629,0.001009078],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843881,0.003173899,0.00002894483,0.0008858199,0.0004626727,0.0003580381,0.00001048647,0.00001400502,0.0106781],"genre_scores_gemma":[0.995306,0.0002428435,0.0001365255,0.00113057,0.0004135468,0.0000124188,0.00009282918,0.00002270161,0.002642629],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5666016,"threshold_uncertainty_score":0.5173428,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2089686819","doi":"10.1016/j.celrep.2014.02.045","title":"Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3","year":2014,"lang":"en","type":"article","venue":"Cell Reports","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":316,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"Associazione Italiana per la Ricerca sul Cancro; Ministero dell’Istruzione, dell’Università e della Ricerca; Nederlandse Organisatie voor Wetenschappelijk Onderzoek","keywords":"KRAS; ERBB3; Kinome; Downregulation and upregulation; Cancer research; Receptor tyrosine kinase; Mutant; Cetuximab; ErbB; MEK inhibitor; Kinase; Colorectal cancer; Biology; Cancer; MAPK/ERK pathway; Signal transduction; Medicine; Cell biology; Internal medicine; Gene; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.008725670807022873,"gpt":0.2299171364603361,"spread":0.2211914656533132,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001569323,0.00007767211,0.0001107578,0.00003124146,0.00002516856,0.000005303644,0.00001674688,0.00009079756,0.00001023378],"category_scores_gemma":[0.00003410044,0.00007826483,0.00002432881,0.00006943805,0.00003184407,0.0000053703,0.00001745738,0.00004772084,3.641458e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001843781,"about_ca_system_score_gemma":0.00004803202,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006830391,"about_ca_topic_score_gemma":0.000423163,"domain_scores_codex":[0.99928,0.00003058646,0.0002391612,0.0002536892,0.00008944662,0.0001071552],"domain_scores_gemma":[0.9996529,0.000004233189,0.0001048375,0.0001436704,0.00005594404,0.00003839619],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.000061605,0.00003125033,0.002645911,0.00006795828,0.000004338423,0.0000217069,0.0001694433,0.00003424849,0.9958029,0.0001741891,0.0005601171,0.0004263218],"study_design_scores_gemma":[0.0002401362,0.00009434978,0.01177584,0.0000498618,0.000009516182,0.00003427793,0.00002695855,0.00000434431,0.9600799,0.000417798,0.02717043,0.0000966038],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959851,0.0006700382,0.0008932212,0.000116534,0.0002277565,0.0001707503,0.00000594117,0.000004310491,0.001926361],"genre_scores_gemma":[0.9989551,0.0001333239,0.0003175196,0.00009744613,0.0001103934,0.00003291359,0.00004140098,0.000008417957,0.0003035049],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03572303,"threshold_uncertainty_score":0.3191547,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2075925391","doi":"10.1016/j.cell.2014.11.053","title":"Pathological Axonal Death through a MAPK Cascade that Triggers a Local Energy Deficit","year":2015,"lang":"en","type":"article","venue":"Cell","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":306,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University; University of Ottawa","funders":"National Institute of Neurological Disorders and Stroke","keywords":"MAPK/ERK pathway; Biology; Cell biology; Neuroscience; Axon; Protein kinase A; Signal transduction; Programmed cell death; Autophagy; Kinase; Apoptosis; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.04483218265073828,"gpt":0.2411561921684091,"spread":0.1963240095176708,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000119842,0.0001817071,0.0001679183,0.00001828073,0.00004765987,0.00001807361,0.000194761,0.0002743475,0.00003840259],"category_scores_gemma":[0.00002147003,0.0001481768,0.0001156239,0.00004640012,0.00008288371,0.000003585565,0.0001241327,0.0000918429,0.00006199744],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002164779,"about_ca_system_score_gemma":0.0001138639,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007308415,"about_ca_topic_score_gemma":0.00001595046,"domain_scores_codex":[0.9989093,0.00007333454,0.0001432402,0.0003822563,0.0001629147,0.0003289864],"domain_scores_gemma":[0.999426,0.00001051386,0.00005380975,0.0002905284,0.00004311147,0.0001760175],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0006030869,0.0004631968,0.002835274,0.00004724181,0.00006610823,0.0005814665,0.0004280669,0.0001919964,0.9309074,0.004873037,0.05468715,0.004315927],"study_design_scores_gemma":[0.0009129616,0.0004747213,0.0001594655,0.000003553777,0.00001816666,0.0001306927,0.0002479622,0.00005821839,0.7183354,0.0006071871,0.2788083,0.0002433351],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9083699,0.002160656,0.03920346,0.00005180149,0.0002826843,0.0000837031,0.00002491981,0.00002937034,0.04979348],"genre_scores_gemma":[0.9951887,0.00009965941,0.001092983,0.0006792683,0.0002514186,0.00002361064,0.0001528739,0.00002031681,0.002491216],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2241212,"threshold_uncertainty_score":0.6042474,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2099259685","doi":"10.1093/annonc/mdi310","title":"Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors","year":2005,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":301,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Bayer (Canada); Juravinski Cancer Centre","funders":"","keywords":"Medicine; Pharmacokinetics; Dosing; Toxicity; Adverse effect; Kinase; Internal medicine; Bay; Pharmacology; Refractory (planetary science); Tyrosine-kinase inhibitor; Cancer; Gastroenterology; Oncology","retraction":null,"screen_n_in":null,"score":{"opus":0.03243005053116366,"gpt":0.3398462573339467,"spread":0.307416206802783,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002912397,0.0001708727,0.0003171094,0.00004814798,0.00005922542,0.000004622375,0.0001853889,0.00007577128,0.00000313869],"category_scores_gemma":[0.0001434681,0.0001074131,0.00004265171,0.0000705299,0.0001473673,0.00000685259,0.0001606302,0.00009227706,2.513961e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000101974,"about_ca_system_score_gemma":0.00009299443,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000003487119,"about_ca_topic_score_gemma":0.000121368,"domain_scores_codex":[0.9988721,0.00009139609,0.0003943442,0.000303228,0.000115812,0.0002231021],"domain_scores_gemma":[0.9991086,0.00009369328,0.0002445798,0.000322197,0.0001464559,0.00008452741],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.02525821,0.01440181,0.01714834,0.0001390934,0.0002100123,0.00001095348,0.002436272,0.0002442628,0.6419104,0.0000510268,0.001381948,0.2968077],"study_design_scores_gemma":[0.03674895,0.09747826,0.08194674,0.0001263192,0.0001145428,0.00001382639,0.0008243746,0.0001463687,0.6124875,0.00001223736,0.1696318,0.0004691409],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9976037,0.0001817553,0.00003998737,0.0005757836,0.00009004283,0.001077362,0.0002175262,0.000002340414,0.0002115672],"genre_scores_gemma":[0.9983802,0.00008721308,0.000291011,0.001007855,0.0001003409,0.00003641596,0.00002739199,0.00001786578,0.00005165176],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2963386,"threshold_uncertainty_score":0.4380178,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1973460380","doi":"10.1016/j.bbamcr.2006.11.001","title":"Atypical mitogen-activated protein kinases: Structure, regulation and functions","year":2006,"lang":"en","type":"review","venue":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":299,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"National Cancer Institute; Canada Research Chairs","keywords":"MAPK7; MAPKAPK2; Mitogen-activated protein kinase; MAPK14; Kinase; MAP kinase kinase kinase; MAP2K7; c-Raf; Biology; Cell biology; ASK1; Protein-Serine-Threonine Kinases; p38 mitogen-activated protein kinases; Mitogen-activated protein kinase kinase; MAPK/ERK pathway; Protein kinase A; Cyclin-dependent kinase 2","retraction":null,"screen_n_in":null,"score":{"opus":0.04603407875994522,"gpt":0.3393542111267232,"spread":0.293320132366778,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004336768,0.0008495632,0.001057356,0.0004554915,0.0003660744,0.000240307,0.0006920732,0.001196646,0.00003682729],"category_scores_gemma":[0.0001594527,0.0007588796,0.0005696317,0.0008121061,0.0004767276,0.00001512322,0.0007280382,0.001114793,0.00005480239],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009619154,"about_ca_system_score_gemma":0.0007876041,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006572929,"about_ca_topic_score_gemma":0.00001193155,"domain_scores_codex":[0.9944921,0.001300641,0.0007134714,0.001696882,0.0008350314,0.0009618505],"domain_scores_gemma":[0.9974279,0.00009462885,0.0003491341,0.001439179,0.0003383204,0.0003508114],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001303527,0.0001758377,1.198869e-7,0.002443553,0.0001820868,0.00002219519,0.00001407992,6.506087e-7,0.9714395,0.0001273437,0.004227513,0.02123678],"study_design_scores_gemma":[0.0003333284,0.0004186276,0.000009759103,0.000541854,0.0001598346,0.00001766708,0.00001012657,0.000004378696,0.5681106,0.0001017216,0.4297346,0.0005574662],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.3321963,0.6608082,0.0001751709,0.00010007,0.0002701124,0.003449353,0.0008246823,0.00007589419,0.002100188],"genre_scores_gemma":[0.2955794,0.6808197,0.0006871147,0.00006379603,0.001122746,0.00067614,0.014192,0.0004418657,0.00641717],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.4255071,"threshold_uncertainty_score":0.9994862,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2144708319","doi":"10.1016/j.ccr.2011.04.002","title":"c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma","year":2011,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":297,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval; Hôtel-Dieu de Québec","funders":"","keywords":"Oncogene; MAPK/ERK pathway; Cancer research; Kinase; Biology; Concomitant; Anti-apoptotic Ras signalling cascade; Lung; Carcinoma; clone (Java method); Cell; Medicine; Cell biology; Internal medicine; Cell cycle; Gene; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.02556869564990289,"gpt":0.2407732591841122,"spread":0.2152045635342093,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007939234,0.0002237121,0.000233841,0.00002944166,0.00009524605,0.00000996838,0.0003000893,0.0001975954,0.0001763439],"category_scores_gemma":[0.000003431486,0.000223149,0.0001538229,0.0000397102,0.00005505798,0.000003746535,0.0001341712,0.00005619324,0.00001216052],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004384689,"about_ca_system_score_gemma":0.000606117,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002319869,"about_ca_topic_score_gemma":0.000267952,"domain_scores_codex":[0.9987512,0.00001723225,0.0003241486,0.0004472661,0.0001077462,0.0003524632],"domain_scores_gemma":[0.9991908,0.000006919325,0.0001762842,0.0003619895,0.0001355338,0.0001284532],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001659507,0.0001054103,0.003525651,0.0002877735,0.00004659699,0.000003265643,0.001700537,0.00000534631,0.9904621,0.000007208976,0.00281373,0.0008763963],"study_design_scores_gemma":[0.001106789,0.0001656847,0.001242484,0.00001614029,0.00006529082,0.000001281377,0.000148822,0.00008512684,0.9655505,0.000003541607,0.03133211,0.0002821898],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9840586,0.001279536,0.006223696,0.000008383688,0.0005089532,0.0004318629,0.0001479153,0.000008404032,0.007332688],"genre_scores_gemma":[0.9864321,0.0001070249,0.00899291,0.0001959641,0.0003359991,0.0001663036,0.0001049933,0.00004301784,0.003621645],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02851838,"threshold_uncertainty_score":0.9099753,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2163563579","doi":"10.1016/s1470-2045(14)70051-8","title":"Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study","year":2014,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":292,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Vemurafenib; Rash; Adverse effect; Internal medicine; Nausea; Clinical endpoint; Population; Dacarbazine; Expanded access; Interim analysis; Dermatology; Surgery; Oncology; Gastroenterology; Clinical trial; Metastatic melanoma; Chemotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.03517410555670822,"gpt":0.3139019102081614,"spread":0.2787278046514532,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008565424,0.0002027964,0.0004658466,0.00003626823,0.0001116208,0.0000320516,0.0007621847,0.00008911734,0.00003136113],"category_scores_gemma":[0.00008864375,0.0001288284,0.00001439172,0.0001283641,0.00009072247,0.00001159497,0.000287441,0.0001742917,0.00002654937],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003805126,"about_ca_system_score_gemma":0.00009390497,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001597276,"about_ca_topic_score_gemma":0.002767909,"domain_scores_codex":[0.9977329,0.0009934418,0.000290902,0.0004320044,0.0001335063,0.0004171795],"domain_scores_gemma":[0.9989026,0.00007119676,0.0001527292,0.0007030849,0.00007953819,0.00009084617],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03173159,0.02464643,0.8312964,0.00009524908,0.0009929746,0.0001539584,0.005303311,0.0005121012,0.03734244,0.001739132,0.003532278,0.06265417],"study_design_scores_gemma":[0.0794867,0.03651858,0.7938864,0.00002380918,0.0002105868,0.00002348256,0.0009328782,0.0006405738,0.002768065,0.0001915384,0.08456129,0.0007560689],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949029,0.00003055717,0.00009614218,0.0002278753,0.000159994,0.001155267,0.00002781649,0.00001745484,0.003381978],"genre_scores_gemma":[0.997593,0.000009733186,0.0008644376,0.0008209051,0.0001577181,0.00008422242,0.0002605195,0.00002835804,0.0001811265],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08102901,"threshold_uncertainty_score":0.5253468,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2079421845","doi":"10.1371/journal.pone.0029336","title":"Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":286,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; National Institute of Arthritis and Musculoskeletal and Skin Diseases; York University; U.S. Department of Veterans Affairs","keywords":"Tumor heterogeneity; Metastatic melanoma; Melanoma; Primary (astronomy); Primary tumor; Medicine; Cancer research; Oncology; Metastasis; Biology; Pathology; Internal medicine; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.02978751268876376,"gpt":0.23192001735447,"spread":0.2021325046657062,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001172115,0.0000743036,0.0001479229,0.00003842729,0.00001695529,0.000005203765,0.00004039191,0.00003007724,0.000006256132],"category_scores_gemma":[0.0000481594,0.0000706585,0.00001561122,0.00003452439,0.00006006102,0.000006470275,0.00007124167,0.00004041252,0.00000153232],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00000471939,"about_ca_system_score_gemma":0.00001504529,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000008684834,"about_ca_topic_score_gemma":0.00002563352,"domain_scores_codex":[0.999499,0.00004367841,0.0001450909,0.0001235073,0.00005727282,0.0001314904],"domain_scores_gemma":[0.9997333,0.00001529945,0.00004776262,0.0001180864,0.00001981279,0.00006573637],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00002884769,0.0004166025,0.1391734,0.0001610634,0.00008479602,0.000001607425,0.0001280625,1.504656e-7,0.859197,0.0000854702,0.00001631073,0.000706654],"study_design_scores_gemma":[0.000552853,0.0002758018,0.1568751,0.00004440417,0.00007098123,0.00001815443,0.00005857071,0.00002461912,0.8417921,0.00007166915,0.0000929853,0.0001227228],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977828,0.001376788,0.000159574,0.00003385431,0.00001538324,0.0001324196,0.00002407912,0.000003434306,0.0004716705],"genre_scores_gemma":[0.9970169,0.00008323684,0.002663048,0.0001037477,0.0000350679,0.0000170512,0.00004014112,0.000008356621,0.00003242439],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01770171,"threshold_uncertainty_score":0.288137,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2740393355","doi":"10.1093/annonc/mdx339","title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":258,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; F. Hoffmann-La Roche; Roche","keywords":"Vemurafenib; Dacarbazine; Medicine; Confidence interval; Hazard ratio; Internal medicine; Metastatic melanoma; Progression-free survival; Melanoma; Gastroenterology; Oncology; Chemotherapy; Cancer; Cancer research","retraction":null,"screen_n_in":null,"score":{"opus":0.04370504422132651,"gpt":0.3263825167606763,"spread":0.2826774725393497,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008253628,0.0001383083,0.0005504427,0.0000433176,0.00008282057,0.000009352439,0.0003513139,0.00008031241,0.000005160834],"category_scores_gemma":[0.0006540362,0.0000898216,0.0001196272,0.0000376459,0.0002812531,0.000008944715,0.0001441733,0.00008718829,0.000001152792],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000007260642,"about_ca_system_score_gemma":0.0001821498,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004802995,"about_ca_topic_score_gemma":0.0009027338,"domain_scores_codex":[0.9983234,0.0005846559,0.0004651765,0.0002555136,0.0001870716,0.0001841595],"domain_scores_gemma":[0.9983073,0.0001571261,0.0006972569,0.0005126448,0.0002876611,0.00003802265],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5510487,0.01158348,0.3915624,0.0001317963,0.002845347,0.0001548763,0.00488879,0.0003911623,0.01678324,0.00154848,0.002321942,0.01673984],"study_design_scores_gemma":[0.1855607,0.007584062,0.7776275,0.00003318727,0.0001085673,0.000003959158,0.0001490577,0.00001527528,0.02801112,0.0002241146,0.0005120104,0.0001703795],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946056,0.00004374517,0.00002036336,0.000338125,0.0001660713,0.0008220389,0.0001047253,0.00000170216,0.003897635],"genre_scores_gemma":[0.9994197,0.00001245961,0.0001136691,0.00009608618,0.0000310503,0.00002966798,0.00006891284,0.00001015166,0.0002182347],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3860652,"threshold_uncertainty_score":0.3662819,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2078902726","doi":"10.1038/nchembio.1629","title":"A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics","year":2014,"lang":"en","type":"article","venue":"Nature Chemical Biology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":248,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Canadian Institutes of Health Research; Cancer Research UK; Wellcome Trust","keywords":"Binding site; Receptor–ligand kinetics; Kinase; Kinetics; Chemistry; Plasma protein binding; Biophysics; MAPK/ERK pathway; Pyrimidine; Biochemistry; Stereochemistry; Biology; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.005112793602613707,"gpt":0.2249571127614532,"spread":0.2198443191588395,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0002157856,0.0002429739,0.0002929147,0.00009470011,0.00003435861,0.00001385115,0.0002209156,0.001436588,0.00002051032],"category_scores_gemma":[0.0005192907,0.0001967798,0.0000717029,0.0002367444,0.0001161992,0.000003059059,0.0001312421,0.0006124372,0.00002019672],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004531044,"about_ca_system_score_gemma":0.00003860605,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000005482575,"about_ca_topic_score_gemma":0.00002659517,"domain_scores_codex":[0.9985924,0.00009859866,0.0002343643,0.0005401919,0.00009021656,0.0004441779],"domain_scores_gemma":[0.999345,0.00007025028,0.000114096,0.0002835199,0.00007645882,0.0001106526],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00007804824,0.00006638663,0.01139465,0.00001015113,0.00003088932,0.000006034985,0.00002622698,5.389735e-7,0.9851373,0.0001554463,0.002622078,0.0004721956],"study_design_scores_gemma":[0.0009849912,0.0004257807,0.0004901736,0.00005075726,0.00001409775,0.00001865479,0.000007286272,0.00002996156,0.9606875,0.00008964667,0.0369068,0.0002943256],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973823,0.0002637042,0.0001264423,0.0002575515,0.0001740441,0.0001472688,0.00009066055,0.00002803513,0.001529984],"genre_scores_gemma":[0.9965953,0.00002960742,0.0006051656,0.0009071662,0.0003116376,0.00001807051,0.001246952,0.00002965249,0.0002564339],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03428472,"threshold_uncertainty_score":0.9998598,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1965097080","doi":"10.1158/1535-7163.mct-04-0297","title":"Raf kinase as a target for anticancer therapeutics","year":2005,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":247,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"MAPK/ERK pathway; Receptor tyrosine kinase; Kinase; Tyrosine kinase; Cancer research; Signal transduction; Biology; Medicine; Cell biology","retraction":null,"screen_n_in":null,"score":{"opus":0.05591067051033215,"gpt":0.3620443422933081,"spread":0.3061336717829759,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002438564,0.0009561764,0.001355752,0.0001316389,0.0001577323,0.00008960727,0.0008062453,0.0009875401,0.00009547202],"category_scores_gemma":[0.00001609642,0.0008477849,0.001179758,0.000233423,0.0001526902,0.0000051411,0.000169137,0.0003743115,0.00004813408],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001334101,"about_ca_system_score_gemma":0.001217433,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001452974,"about_ca_topic_score_gemma":0.00001666475,"domain_scores_codex":[0.9968376,0.0001966337,0.0007067025,0.001068449,0.0003483076,0.0008423753],"domain_scores_gemma":[0.9979401,0.00004011383,0.0004366282,0.001188524,0.0002103047,0.0001843711],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008206576,0.0001249569,0.000002060134,0.002014153,0.001622101,0.0000197067,0.00003281175,0.00001564992,0.009118518,0.0004482844,0.0005853756,0.9859343],"study_design_scores_gemma":[0.000737434,0.0004952103,2.812855e-7,0.0008215375,0.0019751,0.00003573781,0.000008819394,0.00002561212,0.01127334,0.0001771456,0.9834293,0.001020541],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00007692914,0.9884716,0.007155266,0.0001573336,0.000799529,0.001842508,0.000568069,0.00005086054,0.0008778781],"genre_scores_gemma":[0.0001400288,0.9881042,0.002350841,0.003487072,0.00145849,0.001297398,0.0008823769,0.0003541313,0.001925444],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9849138,"threshold_uncertainty_score":0.9993973,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2137990944","doi":"10.1186/1756-8722-3-8","title":"From basic research to clinical development of MEK1/2 inhibitors for cancer therapy","year":2010,"lang":"en","type":"review","venue":"Journal of Hematology & Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":244,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"National Cancer Institute; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Cancer research; Regulator; Cancer; Kinase; Receptor tyrosine kinase; MAPK/ERK pathway; Hematology; Tyrosine kinase; Signal transduction; Function (biology); Hyperactivation; Medicine; Biology; Internal medicine; Cell biology; Gene; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.233354112101503,"gpt":0.5308665528212848,"spread":0.2975124407197818,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00337264,0.0003296162,0.002928101,0.0003398744,0.00009118459,0.000007916285,0.000798168,0.001972544,0.00006939787],"category_scores_gemma":[0.0008034293,0.0002409176,0.0008023123,0.0001557138,0.0002611871,0.000003368598,0.0002377217,0.001123783,0.00001461433],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008373987,"about_ca_system_score_gemma":0.005838048,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000107677,"about_ca_topic_score_gemma":0.0001874918,"domain_scores_codex":[0.995492,0.0008636026,0.002436747,0.0004790915,0.0002567903,0.0004717121],"domain_scores_gemma":[0.9958784,0.0009472509,0.001626813,0.0004338222,0.0008407733,0.0002729563],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003798131,0.0003502489,0.0001090451,0.0006378561,0.0007219483,0.00004166293,0.000136578,1.194199e-7,0.002999147,0.00007270773,0.02677259,0.9677783],"study_design_scores_gemma":[0.000922996,0.002415407,0.00001197216,0.0009634682,0.0001672248,0.0002946741,0.00004894797,8.859757e-8,0.009611187,0.00009695093,0.9852634,0.0002036797],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.02971811,0.9650728,0.000282555,0.0002955501,0.003567605,0.0008392641,0.00007166103,0.000002821783,0.0001496988],"genre_scores_gemma":[0.0002349167,0.9828714,0.01321102,0.0001591959,0.003019625,0.000205882,0.00007640992,0.00006048927,0.0001610545],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9675746,"threshold_uncertainty_score":0.9997979,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2756647112","doi":"10.1158/1535-7163.mct-17-0456","title":"Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)","year":2017,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":234,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Phenomenome Discoveries (Canada)","funders":"","keywords":"MAPK/ERK pathway; Medicine; In vivo; Melanoma; Cancer research; Cancer; Pharmacology; Phosphorylation; Potency; MEK inhibitor; Targeted therapy; In vitro; Internal medicine; Biology; Cell biology; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.03944351150700175,"gpt":0.3106321426094479,"spread":0.2711886311024461,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005983174,0.0003350946,0.0002804821,0.00002667272,0.0006913702,0.0001749053,0.0007290062,0.0002290962,0.00001004727],"category_scores_gemma":[0.00006628419,0.0002038801,0.0001312498,0.0001109119,0.0002948581,0.00001594359,0.0002242417,0.0005167582,0.000001683382],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007914755,"about_ca_system_score_gemma":0.0004856873,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004249576,"about_ca_topic_score_gemma":0.000813902,"domain_scores_codex":[0.9980711,0.0001957709,0.0002758938,0.0006116888,0.0003113881,0.0005341897],"domain_scores_gemma":[0.9984624,0.00005429765,0.000393018,0.0008553367,0.0001618544,0.00007310725],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0004083852,0.00010762,0.00444972,0.00002244973,0.0002305583,0.00001111606,0.00044132,0.0010566,0.982826,0.00004002536,0.00005906405,0.01034715],"study_design_scores_gemma":[0.00122398,0.0002889523,0.003783432,0.00009224686,0.00007850915,0.000007154632,0.00012631,0.0006650849,0.9742095,0.00003835936,0.01911891,0.0003675025],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9881299,0.002235091,0.005285225,0.002857035,0.0003002044,0.0007680457,0.0000460005,0.0000191284,0.000359434],"genre_scores_gemma":[0.9971607,0.0001898927,0.0003062163,0.001269556,0.0005307146,0.0003141504,0.00001176661,0.0000701098,0.0001469397],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01905984,"threshold_uncertainty_score":0.8313987,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2258535515","doi":"10.1158/2159-8290.cd-15-1336","title":"Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma","year":2015,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":230,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK; Wellcome Trust; Wellcome","keywords":"Melanoma; Precision medicine; Medicine; Personalized medicine; Liquid biopsy; Targeted therapy; Exome sequencing; Biopsy; Oncology; Cancer research; Exome; Internal medicine; Mutation; Bioinformatics; Pathology; Cancer; Biology; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.02417063816839317,"gpt":0.2713803003633998,"spread":0.2472096621950067,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008082065,0.00009050785,0.0001503305,0.00003428381,0.00001489069,0.000004444446,0.00006116495,0.0000705493,0.000002355235],"category_scores_gemma":[0.00004458859,0.00007667702,0.00002698636,0.00005196734,0.0001109603,0.000007494504,0.00003572911,0.00002439009,1.99477e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003189113,"about_ca_system_score_gemma":0.0001428762,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003385498,"about_ca_topic_score_gemma":0.0001582525,"domain_scores_codex":[0.9994183,0.0000189713,0.0001614086,0.0002093866,0.00007164486,0.0001202987],"domain_scores_gemma":[0.9996396,0.000008242212,0.00008964619,0.0001429858,0.00006213395,0.00005744465],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0005064385,0.00001491369,0.003333046,0.00005338629,0.00001949949,6.171129e-7,0.0005866466,0.00001992973,0.9925637,0.0002903626,0.0009526859,0.00165874],"study_design_scores_gemma":[0.002882955,0.001888289,0.001234208,0.00007951388,0.00003277088,0.000007200847,0.001559996,0.0001219175,0.9415138,0.0001972529,0.05026153,0.0002205998],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901218,0.005998166,0.002987881,0.0001425803,0.0001317162,0.0002939916,0.0000764054,0.000003802369,0.0002435962],"genre_scores_gemma":[0.9988398,0.0002691273,0.0001553605,0.0001669527,0.0001480604,0.0001753902,0.0001382192,0.00001126427,0.00009584367],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05104997,"threshold_uncertainty_score":0.3126798,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4241605155","doi":"10.1016/j.ejca.2012.06.013","title":"Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2012","year":2012,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":229,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"Cancer Research UK","keywords":"Medicine; Ipilimumab; Melanoma; Guideline; Oncology; Vemurafenib; Internal medicine; Stage (stratigraphy); Systemic therapy; Adjuvant therapy; Skin cancer; Cancer; Surgery; Dermatology; Breast cancer; Immunotherapy; Pathology; Cancer research; Metastatic melanoma","retraction":null,"screen_n_in":null,"score":{"opus":0.02186877716028896,"gpt":0.2939923508756755,"spread":0.2721235737153865,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005373071,0.000144293,0.0002000025,0.00005488621,0.00003939696,0.000008828515,0.0001162366,0.00001957381,0.0001007781],"category_scores_gemma":[0.00002277874,0.0001072859,0.0001172305,0.00003363803,0.00007897287,0.000006439956,0.00009010505,0.00004843455,0.000009547345],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001598511,"about_ca_system_score_gemma":0.00004549365,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000002527004,"about_ca_topic_score_gemma":0.000006563845,"domain_scores_codex":[0.9988063,0.0003289067,0.0004684728,0.0001138043,0.0001028365,0.0001796919],"domain_scores_gemma":[0.9991208,0.00001401531,0.0003724738,0.0001804918,0.0001396029,0.0001726013],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00112851,0.0007785621,0.09784544,0.00005877102,0.0006394321,0.0003020621,0.0007492624,0.0001953598,0.3584085,0.00003640344,0.115179,0.4246787],"study_design_scores_gemma":[0.002150078,0.001971819,0.04530575,0.00008286115,0.000152709,0.000115075,0.00008334551,0.000009666508,0.1442134,0.000003635474,0.8057063,0.0002054331],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9669774,0.02678214,0.0004290786,0.0007223277,0.0004452781,0.00007512426,0.00004889371,0.000003562952,0.00451622],"genre_scores_gemma":[0.9952442,0.001842096,0.001313735,0.000196635,0.001062868,0.000001672551,0.00001607928,0.00003401763,0.0002886825],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6905273,"threshold_uncertainty_score":0.4374991,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3090469545","doi":"10.1200/jco.20.00995","title":"Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":227,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Royal Victoria Hospital; McGill University; University of British Columbia; BC Cancer Agency","funders":"Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Melanoma; Oncology; Internal medicine; Metastatic melanoma; Ipilimumab; Cancer research; Cancer; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.02934943225884844,"gpt":0.3323646425640745,"spread":0.303015210305226,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004175025,0.0001558307,0.0008010868,0.0000354453,0.00002284514,0.00000690355,0.0002565779,0.0002704643,0.00002644117],"category_scores_gemma":[0.0008369702,0.00009853877,0.000142632,0.0001150093,0.0001108397,0.00001261629,0.00007018324,0.0004309888,0.00001142241],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001920012,"about_ca_system_score_gemma":0.0006083183,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00000476009,"about_ca_topic_score_gemma":0.00006093914,"domain_scores_codex":[0.9981381,0.0002073079,0.0009583982,0.0002508349,0.0002290319,0.000216357],"domain_scores_gemma":[0.9983197,0.0001366277,0.0008011399,0.0001742759,0.0002929824,0.0002752184],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01003486,0.0005988867,0.9760289,0.00001027206,0.0001768149,0.0001294032,0.00004564678,0.00009188448,0.0005786257,0.00002378343,0.001870942,0.01041001],"study_design_scores_gemma":[0.01859134,0.06070517,0.8515381,0.00002855975,0.00007131189,0.00001609894,0.00009100756,0.000006771865,0.0006033509,0.00002064313,0.06812043,0.0002072691],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966176,0.00008215188,0.0001055245,0.001378581,0.0003158374,0.0001427555,0.000005271531,0.00000396734,0.001348333],"genre_scores_gemma":[0.9930516,0.00006376246,0.003451429,0.002950782,0.0003257519,0.000001756003,0.0000135891,0.00002058591,0.0001207832],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1244908,"threshold_uncertainty_score":0.4018294,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2022371765","doi":"10.2741/3003","title":"The RSK factors of activating the Ras/MAPK signaling cascade","year":2008,"lang":"en","type":"review","venue":"Frontiers in bioscience","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":222,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute for Research in Immunology and Cancer","funders":"National Cancer Institute; Terry Fox Foundation","keywords":"MAPK/ERK pathway; Gene isoform; Ribosomal s6 kinase; Kinase; Cell biology; Biology; Signal transduction; Effector; Protein kinase A; MAPK cascade; Gene; Biochemistry; PI3K/AKT/mTOR pathway; P70-S6 Kinase 1","retraction":null,"screen_n_in":null,"score":{"opus":0.0306186198857923,"gpt":0.2817528382859497,"spread":0.2511342184001574,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003934387,0.0002650848,0.0004922854,0.0000715381,0.0003308752,0.00002903404,0.001090454,0.0002488775,0.000001169771],"category_scores_gemma":[0.0004141788,0.0001347812,0.0002625259,0.0003856457,0.0005336956,0.0000046583,0.0002014002,0.0002696092,9.517237e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003568414,"about_ca_system_score_gemma":0.0003317805,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002324257,"about_ca_topic_score_gemma":0.000005794496,"domain_scores_codex":[0.9983479,0.0001903721,0.0004355541,0.0004213184,0.0002412899,0.000363518],"domain_scores_gemma":[0.9988723,0.0001107964,0.0003948511,0.0005372979,0.00003387667,0.00005082384],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001420396,0.00005547666,0.0009959175,0.001074089,0.0001157141,0.00001016402,0.0004440077,0.00001350229,0.01377022,0.0001038965,0.0131264,0.9702764],"study_design_scores_gemma":[0.00005518179,0.00005644156,0.00003994926,0.0005928581,0.00001950501,0.00001669299,0.0002399994,0.00001085679,0.01149044,0.00001623184,0.9872622,0.0001995839],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.003265575,0.9936206,0.001097701,0.00001293118,0.001298968,0.0003756691,0.00002662827,0.000005305235,0.0002966695],"genre_scores_gemma":[0.002907577,0.9959083,0.0006959472,0.0000205587,0.0001299093,0.00002681175,0.00002296903,0.00001959184,0.0002683866],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9741359,"threshold_uncertainty_score":0.5496218,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2138718238","doi":"10.1523/jneurosci.5227-03.2004","title":"Mitogen- and Stress-Activated Protein Kinase 1 Mediates cAMP Response Element-Binding Protein Phosphorylation and Activation by Neurotrophins","year":2004,"lang":"en","type":"article","venue":"Journal of Neuroscience","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":222,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Pediatric Oncology Group","funders":"National Institute of Mental Health; Medical Research Council; Merck KGaA; GlaxoSmithKline; National Institutes of Health; Pfizer","keywords":"CREB; Protein kinase A; Ribosomal s6 kinase; Cell biology; Mitogen-activated protein kinase kinase; Phosphorylation; Neurotrophin; Kinase; MAP kinase kinase kinase; Biology; Molecular biology; Transcription factor; Biochemistry; Protein kinase B; P70-S6 Kinase 1; Receptor; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.01271564260963545,"gpt":0.2392784170570495,"spread":0.2265627744474141,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002624813,0.000111816,0.000100734,0.00007094864,0.0001254472,0.00005872736,0.0001087041,0.00005607332,0.000001033041],"category_scores_gemma":[0.0005094011,0.000095874,0.00002441209,0.0001151784,0.00009579174,0.00003928633,0.00005374999,0.0001179489,2.545054e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001868576,"about_ca_system_score_gemma":0.0001009389,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000004949688,"about_ca_topic_score_gemma":0.000001024352,"domain_scores_codex":[0.9990974,0.00009141954,0.000221942,0.0002195564,0.0002103072,0.0001593734],"domain_scores_gemma":[0.9994169,0.0000111117,0.0002826181,0.0001001866,0.00007229553,0.0001168326],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0004075785,0.00004350652,0.0004363764,0.00001009058,0.000002284107,0.00001062993,0.00005240047,0.00002044003,0.9985973,0.00001434743,0.0000199272,0.000385134],"study_design_scores_gemma":[0.0007276388,0.001030666,0.005582298,0.00004681191,0.000004212741,0.00004978452,0.00003903965,0.00001382486,0.9912523,0.00004243754,0.001116285,0.00009470141],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9985749,0.0001033219,0.000576053,0.0003531966,0.0001076497,0.0002559152,0.00001952123,0.000004214707,0.000005292444],"genre_scores_gemma":[0.9994364,0.0000564202,0.00026939,0.00007075271,0.0000546753,0.000007881218,0.000004910717,0.00001012189,0.00008946358],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007344985,"threshold_uncertainty_score":0.3909628,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2099267053","doi":"10.1101/gad.962902","title":"KSR is a scaffold required for activation of the ERK/MAPK module","year":2002,"lang":"en","type":"article","venue":"Genes & Development","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":220,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Montreal Clinical Research Institute","funders":"National Cancer Institute","keywords":"MAPK/ERK pathway; Cell biology; Scaffold protein; Biology; Caenorhabditis elegans; Kinase; Phosphorylation; Scaffold; Suppressor; MEK inhibitor; Signal transduction; Genetics; Cancer; Computer science; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.02668381207863523,"gpt":0.2261812319709946,"spread":0.1994974198923594,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008349195,0.0000994139,0.00009040872,0.0000191256,0.00008992713,0.000006981827,0.0001606245,0.0000829016,0.00003514455],"category_scores_gemma":[0.00001893159,0.00007569392,0.0000659358,0.00005699885,0.00002212416,0.000002473367,0.00008360029,0.00001693246,0.000008387282],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001449624,"about_ca_system_score_gemma":0.00005384643,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000002673842,"about_ca_topic_score_gemma":0.000003928999,"domain_scores_codex":[0.9993293,0.00001446902,0.0001832018,0.0002032502,0.0001105541,0.0001591741],"domain_scores_gemma":[0.9995502,0.000004146132,0.00008713809,0.0002566518,0.00007065124,0.00003119501],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00001512078,0.00004180487,0.0004827459,0.00002736734,0.00004220386,9.98354e-8,0.0002462656,0.00000979886,0.9595992,0.00009203381,0.008355424,0.03108796],"study_design_scores_gemma":[0.0002562156,0.00004235779,0.002397343,0.00001146665,0.000005761251,0.00000148575,0.00002205888,0.00005690223,0.814069,0.00005753539,0.1829906,0.00008934049],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948313,0.0004922714,0.002762337,0.0002215307,0.00017116,0.0003254508,0.00001230536,0.000007188359,0.001176464],"genre_scores_gemma":[0.9907537,0.00007363257,0.005483085,0.0003537844,0.0001042821,0.00008953288,0.00003721193,0.00001418703,0.00309061],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1746351,"threshold_uncertainty_score":0.3086708,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2120136426","doi":"10.1139/o04-121","title":"The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling","year":2005,"lang":"en","type":"review","venue":"Biochemistry and Cell Biology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":217,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":true,"about_ca":false},"ca_institutions":"University of Manitoba","funders":"National Cancer Institute; Canadian Institutes of Health Research; Canada Research Chairs; CancerCare Manitoba Foundation","keywords":"Chromatin remodeling; MAPK/ERK pathway; Cell biology; Histone H3; Chromatin; Biology; Signal transduction; Histone; Kinase; Mitogen-activated protein kinase; Phosphorylation; Protein kinase A; Chromatin immunoprecipitation; Cancer research; Gene expression; Gene; Genetics; Promoter","retraction":null,"screen_n_in":null,"score":{"opus":0.02077710537181383,"gpt":0.2729986952507849,"spread":0.2522215898789711,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002406806,0.0004372514,0.0005705628,0.00002304329,0.0002768471,0.0000398715,0.0002276318,0.0008918883,0.00003187521],"category_scores_gemma":[0.000019872,0.0003034496,0.0001897961,0.00005550213,0.0002613894,0.000002486169,0.0001242674,0.0002708735,0.00000375958],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002039318,"about_ca_system_score_gemma":0.0002470287,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001314583,"about_ca_topic_score_gemma":0.000008387839,"domain_scores_codex":[0.9983195,0.0001050134,0.0004307129,0.0007157279,0.00006031131,0.0003687537],"domain_scores_gemma":[0.9991949,0.00005000633,0.0002377599,0.0003486174,0.00004025395,0.0001284324],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001557044,0.00001578605,0.000001813895,0.001357647,0.00005572605,0.000001181952,0.000008986663,3.759058e-7,0.1990035,0.00001609861,0.0003113862,0.7992119],"study_design_scores_gemma":[0.0002002812,0.00009288538,3.214788e-7,0.0003346642,0.0001396769,0.0000806285,0.00002349635,0.00001126322,0.08332928,0.00001638285,0.9154218,0.000349339],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.006864643,0.9913201,0.00006195472,0.0000403631,0.0002163462,0.0002672825,0.0001558487,0.0000159929,0.001057451],"genre_scores_gemma":[0.00461219,0.9914133,0.0001115734,0.0000401103,0.001326798,0.0001188238,0.0005851567,0.00003533156,0.001756747],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9151104,"threshold_uncertainty_score":0.9999418,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2114067189","doi":"10.1158/0008-5472.can-13-2381","title":"ERKs in Cancer: Friends or Foes?","year":2014,"lang":"en","type":"review","venue":"Cancer Research","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":211,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Canadian Institutes of Health Research","keywords":"Cancer; Medicine; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.207352210794642,"gpt":0.5086070552722703,"spread":0.3012548444776283,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009188819,0.0003153833,0.0008970902,0.0002634352,0.00009336948,0.00004592184,0.0007455641,0.0006335603,0.0005253478],"category_scores_gemma":[0.000141769,0.0002300364,0.0002211111,0.0004853336,0.0001490624,0.000002295958,0.0003945347,0.000772198,0.00007946293],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001996305,"about_ca_system_score_gemma":0.002207782,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006878316,"about_ca_topic_score_gemma":0.002290152,"domain_scores_codex":[0.9971898,0.000469806,0.0004086361,0.0007853186,0.0003737985,0.0007726263],"domain_scores_gemma":[0.9987296,0.00006953529,0.0001088644,0.000750292,0.0001519015,0.0001897782],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005402098,0.00003577844,0.00002670709,0.007714448,0.0000970388,0.00003531152,0.00002035518,0.00000122105,0.0005462838,0.00009430394,0.02251323,0.9688613],"study_design_scores_gemma":[0.0002421024,0.0002150653,0.000003500518,0.003431557,0.00004044995,0.000009949733,0.000008849664,0.00000119715,0.0005796151,0.00001457639,0.9951667,0.0002864955],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004297277,0.9947413,0.00001369955,0.00004449326,0.0004297271,0.0006587615,0.0001585946,0.000009068554,0.003514592],"genre_scores_gemma":[0.0002143935,0.9851121,0.00002144851,0.00004630652,0.001531634,0.002010187,0.000215056,0.00008135809,0.01076746],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9726534,"threshold_uncertainty_score":0.9380613,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1974404622","doi":"10.2741/3086","title":"The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases)","year":2008,"lang":"en","type":"review","venue":"Frontiers in bioscience","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":198,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Medical Research Council; Canadian Institutes of Health Research; European Commission","keywords":"Kinase; EIF4E; MAPK7; Mitogen-activated protein kinase; Cell biology; Translation (biology); Receptor tyrosine kinase; MAP2K7; Alternative splicing; Biology; Scaffold protein; MAPK14; Signal transduction; MAP kinase kinase kinase; Cyclin-dependent kinase 2; Biochemistry; Protein kinase A; Gene isoform; Gene; Messenger RNA","retraction":null,"screen_n_in":null,"score":{"opus":0.02210076121847201,"gpt":0.2857966600787956,"spread":0.2636958988603236,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007007718,0.0008218605,0.001133973,0.0002779613,0.0007956919,0.000228712,0.001816289,0.0005329351,0.00001339292],"category_scores_gemma":[0.0007917911,0.000579361,0.000639467,0.0005962816,0.000694012,0.00002649424,0.0005358654,0.0007244545,0.00004476183],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001858157,"about_ca_system_score_gemma":0.0007758915,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007827411,"about_ca_topic_score_gemma":0.0000779994,"domain_scores_codex":[0.9955299,0.0004614712,0.001007988,0.001414867,0.0004967262,0.00108898],"domain_scores_gemma":[0.9975883,0.0002033571,0.0007267439,0.001127681,0.0001161449,0.0002377746],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004112677,0.0001508776,0.0002930661,0.001834012,0.00008445045,0.0003154792,0.00009293194,0.000005336612,0.002622589,0.0001297228,0.07269377,0.9217367],"study_design_scores_gemma":[0.0001834672,0.0002363917,0.000007216051,0.003654768,0.00006078266,0.0001028176,0.0003210122,0.00008419473,0.00252811,0.00003722639,0.9920587,0.0007253202],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003003578,0.9907103,0.002031351,0.00007090384,0.005061822,0.0008306886,0.00009512259,0.00004118443,0.0008583027],"genre_scores_gemma":[0.0007014202,0.9926311,0.003641625,0.0001300293,0.000726773,0.0002038357,0.0002187305,0.00008261627,0.001663803],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9210113,"threshold_uncertainty_score":0.9996658,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}